burstthepulp的个人主页 - 老虎社区

burstthepulp

burstthepulp

暂无个人介绍

IP属地：未知

5关注

2粉丝

0主题

0勋章

2021-08-18

Honestly in my humble opinion, with the strong and rapid spread of the delta variant, there's going to be an increase in demand for vaccine jabs and booster jabs - making $Moderna, Inc.(MRNA)$a very much keep-worthy stock vs. dumping it.

2021-11-19

about time! so many different studies have showed increased protection with $Moderna, Inc.(MRNA)$

Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older<blockquote>Moderna宣布FDA授权美国18岁及以上成年人接种新冠疫苗加强剂量</blockquote>

2021-12-09

to the moon! [Cool] [Cool]

Apple shares rose nearly 2% to a new high<blockquote>苹果股价上涨近2%，创新高</blockquote>

2021-12-01

A good time to buy in $Sea Ltd(SE)$[Cool]

抱歉，原内容已删除

2021-11-26

To the moon! $Moderna, Inc.(MRNA)$[财迷] [财迷]

Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.<blockquote>疫苗股早盘持续走高，Moderna股价大涨超23%。</blockquote>

2021-12-09

very insightful article and shed some light on why $Grab Holdings(GRAB)$is doing so badly. only wish it came out earlier [Cry]

抱歉，原内容已删除

2021-12-09

wanted to buy the dip but there isn't really a dip with [LOL]

Amazon shares fell slightly by 0.5% in premarket trading<blockquote>亚马逊股价在盘前交易中小幅下跌0.5%</blockquote>

2021-12-18

mmmm

Why Pfizer and Johnson & Johnson Fell on Friday<blockquote>辉瑞和强生周五为何下跌</blockquote>

2021-11-29

[财迷]

抱歉，原内容已删除

2021-12-18

buy at dip? [Cool]

Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group<blockquote>由于印度暂停2019年与Future Group的交易，亚马逊早盘下跌近2%</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4089880892731870","uuid":"4089880892731870","gmtCreate":1626780217195,"gmtModify":1629265225755,"name":"burstthepulp","pinyin":"burstthepulp","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":5,"tweetSize":16,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.02","exceedPercentage":"80.72%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.12.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.07","exceedPercentage":"60.87%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":693612253,"gmtCreate":1640012711495,"gmtModify":1640012711612,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"wonder why the shares isn't growing 37-fold&nbsp;[Smug]&nbsp;","listText":"wonder why the shares isn't growing 37-fold&nbsp;[Smug]&nbsp;","text":"wonder why the shares isn't growing 37-fold [Smug]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693612253","repostId":"2192318994","repostType":2,"isVote":1,"tweetType":1,"viewCount":2595,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693134149,"gmtCreate":1639983725886,"gmtModify":1639983734484,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"Holding my breath as I await the climb&nbsp;[LOL]&nbsp;","listText":"Holding my breath as I await the climb&nbsp;[LOL]&nbsp;","text":"Holding my breath as I await the climb [LOL]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693134149","repostId":"1109541249","repostType":4,"repost":{"id":"1109541249","kind":"news","pubTimestamp":1639972523,"share":"https://www.laohu8.com/m/news/1109541249?lang=zh_CN&edition=full","pubTime":"2021-12-20 11:55","market":"us","language":"en","title":"Sea Stock: Down 43% From Its High, is a Buy Now?<blockquote>Sea股票：较高点下跌43%，现在值得买入吗？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1109541249","media":"Seeking Alpha","summary":"Summary\n\nSea Limited stock has been battered recently as growth stocks sold off massively in the mar","content":"<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>Sea Limited stock has been battered recently as growth stocks sold off massively in the market.</li>  <li>However, we believe that the fundamental thesis on its rapid growth remains robust.</li>  <li>We discuss why investors should capitalize on its recent significant correction to add exposure.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/aa5cbe0a30acc723a2c6f62300024002\" tg-width=\"1536\" tg-height=\"1024\" referrerpolicy=\"no-referrer\"><span>kokkai/iStock Unreleased via Getty Images</span></p><p><blockquote><ul><li>由于成长型股票在市场上大量抛售，Sea Limited的股票最近遭受重创。</li><li>然而，我们认为其快速增长的基本论点仍然强劲。</li><li>我们讨论了为什么投资者应该利用其最近的重大调整来增加风险敞口。</li></ul><p class=\"t-img-caption\"><span>kokkai/iStock未通过Getty Images发布</span></p></blockquote></p><p> <b>Investment Thesis</b></p><p><blockquote><b>投资论文</b></blockquote></p><p> Sea Limited(NYSE:SE)&nbsp;stock is one of our highest conviction growth stocks that has been severely battered over the last month. Since its recent all-time high (ATH) in October, its price has dropped by a dramatic 43%. Many reasons have been presented on why the stock has fallen. We exhort investors not to read too much into them. We believe nothing material has changed from its fundamental thesis. The stock has had a remarkable run in 2021 relative to its gaming peers or e-tailer peers. Therefore, profit-taking of this extent should not be surprising as fear struck growth stocks.</p><p><blockquote>Sea Limited（纽约证券交易所股票代码：SE）股票是我们最有信心的成长型股票之一，但在上个月遭受了严重打击。自10月份创下历史新高(ATH)以来，其价格已大幅下跌43%。关于该股下跌的原因有很多。我们敦促投资者不要对他们解读太多。我们认为它的基本论点没有任何实质性的改变。相对于游戏同行或电子零售商同行，该股在2021年表现出色。因此，随着恐惧袭击成长型股票，这种程度的获利了结并不令人意外。</blockquote></p><p> Moreover, the recent significant correction in growth stocks across the market has also hit SE stock hard. But, we are not concerned. Significant volatility will always be a factor influencing the performance of growth stocks like SE in the short term.</p><p><blockquote>此外，近期全市场成长股的大幅回调也重创了SE股。但是，我们并不担心。短期内，大幅波动始终是影响SE等成长型股票表现的一个因素。</blockquote></p><p> Notably, we observed that the consensus target price on SE stock had been revised upwards since its FQ3 report card. Moreover, the gap between its price target and its current stock price has been greater than its last significant correction in April/May.</p><p><blockquote>值得注意的是，我们观察到，自第三季度成绩单以来，SE股票的共识目标价已向上修正。此外，其目标价与当前股价之间的差距已大于4月/5月的上次大幅调整。</blockquote></p><p> Our internal DCF valuation model also points to a stock that is now significantly undervalued. Thanks to the market's myopia, we have been presented with another fantastic opportunity since April/May to add SE stock with great fervor again.</p><p><blockquote>我们的内部DCF估值模型也指向一只目前被严重低估的股票。由于市场的短视，自4月/5月以来，我们又迎来了一个绝佳的机会，再次以极大的热情增持SE股票。</blockquote></p><p> We discuss why we think investors should not miss this incredible opportunity to add exposure to an outstanding growth stock.</p><p><blockquote>我们讨论了为什么我们认为投资者不应该错过这个增加对优秀成长型股票投资的绝佳机会。</blockquote></p><p> <b>SE Stock YTD Performance</b></p><p><blockquote><b>SE股票年初至今表现</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6c191d1f0f6a10e392845cdbda1264aa\" tg-width=\"640\" tg-height=\"331\" referrerpolicy=\"no-referrer\"><span>SE stock YTD performance (as of 17 December'21).</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股票年初至今表现（截至21年12月17日）。</span></p></blockquote></p><p> As a result of the significant correction recently, SE stock's YTD return has dropped to 6.9%, thus underperforming the market. Notably, its YTD gain was as high as 80% in October/early November. Despite that, the stock is still outperforming its e-tailer and gaming peers, as shown above.</p><p><blockquote>由于近期大幅调整，SE股票年初至今的回报率已降至6.9%，表现逊于大盘。值得注意的是，10月/11月初，其年初至今涨幅高达80%。尽管如此，该股的表现仍然优于电子零售商和游戏同行，如上所示。</blockquote></p><p> <b>Sea Stock Estimates Have Consistently Been Revised Upwards</b></p><p><blockquote><b>海洋库存估计不断上调</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8555128e2a30e924dd6c2dd162a27eea\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Sea Limited revised revenue mean consensus estimates. Data source: S&amp;P Capital IQ, Seeking Alpha</span></p><p><blockquote><p class=\"t-img-caption\"><span>Sea Limited修正后的收入平均共识估计。数据来源：S&amp;P Capital IQ、Seeking Alpha</span></p></blockquote></p><p> Readers can quickly observe that the company's revenue consensus estimates for FY21-23 have consistently been revised upwards over the last five months. These revisions lend credence to the robust growth prospects of the company over the next two years. Notably, Sea Limited's revenue is estimated to increase at a phenomenal CAGR of 42.8% through FY23.</p><p><blockquote>读者可以很快观察到，该公司对2021-23财年的收入共识预期在过去五个月中一直在上调。这些修正为公司未来两年的强劲增长前景增添了信心。值得注意的是，Sea Limited的收入预计将通过2023财年以42.8%的惊人复合年增长率增长。</blockquote></p><p> There were concerns over the growth rates of its Garena gaming arm in its FQ3 report card.We also explained in our previous article&nbsp;that Sea Limited has clearly explained that investors should expect normalization in Garena's growth after two spectacular years. However, its monetization capability continues to dazzle. Therefore, we are confident that Garena can continue its robust monetization strategies moving forward.</p><p><blockquote>人们对其第三季度成绩单中Garena游戏部门的增长率感到担忧。我们在上一篇文章中还解释说，Sea Limited已经明确解释说，投资者应该预计Garena的增长在经历了两年的辉煌之后将正常化。然而，其变现能力继续令人眼花缭乱。因此，我们相信Garena能够继续其稳健的货币化战略。</blockquote></p><p> Moreover, data from Sensor Tower's recent gaming statistics continue to point to sturdy performance from its Free Fire game. It continues to be ranked among the&nbsp;top ten mobile games in terms of overall gaming revenue&nbsp;in November. Moreover, it's also ranked#2 in overall downloadsacross both the App Store and Google Play. Notably, it's also among&nbsp;eight games globally whose annual revenue crossed $1B&nbsp;as of 14 December. Therefore, we think the sentiments and chatter about Free Fire's \"one-shot wonder\" have been overblown.</p><p><blockquote>此外，Sensor Tower最近的游戏统计数据继续表明其Free Fire游戏的强劲性能。继续位列11月整体游戏收入排名前十的手游。此外，它在App Store和Google Play的总下载量中也排名第二。值得注意的是，截至12月14日，它也是全球年收入超过10亿美元的八款游戏之一。因此，我们认为关于Free Fire的“一次性奇迹”的情绪和喋喋不休被夸大了。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/51247ba1efd7fa6d333b482446e94c9a\" tg-width=\"515\" tg-height=\"380\" referrerpolicy=\"no-referrer\"><span>Global games market forecast. Source: Google, Newzoo</span></p><p><blockquote><p class=\"t-img-caption\"><span>全球游戏市场预测。资料来源：谷歌、Newzoo</span></p></blockquote></p><p></p><p> In addition, the global gaming market is estimated to experience a slight decline to $175.8B after last year's massive 23% growth to $177.8B. However, given Garena's impressive growth in FY21 despite the decline in the global market, we believe it validates its business model and prospects. Notably, the gaming market is expected to reverse its decline moving forward. Therefore, Garena's leadership in mobile gaming could continue to propel its growth underpinned by the recovery in the global gaming market.</p><p><blockquote>此外，全球游戏市场在去年大幅增长23%至$177.8 B后，预计将小幅下降至$175.8 B。然而，尽管全球市场下滑，但鉴于Garena在21财年仍取得了令人印象深刻的增长，我们相信它验证了其商业模式和前景。值得注意的是，游戏市场预计将扭转未来的颓势。因此，在全球游戏市场复苏的支持下，Garena在移动游戏领域的领导地位可能会继续推动其增长。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0a0612da9a19f7b7198d43213b4f4470\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Shopee adjusted EBITDA per order. Data source: Company filings</span></p><p><blockquote><p class=\"t-img-caption\"><span>Shopee调整了每个订单的EBITDA。数据来源：公司备案</span></p></blockquote></p><p> But, some investors may have been spooked by Shopee's (Sea Limited's e-commerce arm) continued expansion into new geographical markets. Notably, Shopee continues to report adjusted EBITDA loss per order, as shown above. Therefore, some investors might have been concerned about whether the company's plate is getting too much to handle. Over the last three months, the company has entered into new markets such as India, France, Spain, and Poland. They are in addition to its battle with MercadoLibre (MELI) in Latin America, particularly Brazil. As a result, there are concerns on whether Sea Limited could continue its adroit execution in these markets while still making losses. We believe such concerns are valid. However, Sea Limited has shown its tremendous capability in penetrating the most important markets where the incumbents have strong leadership. It includes Lazada (BABA) in Southeast Asia, MercadoLibre in Brazil, and Tokopedia in Indonesia. Shopee was never the first-mover. But, it took advantage as the \"late-comer\" as it sought to compete with the incumbents. It's important to note that Sea Limited is not averse to competition. It has thrived against the incumbents and has made the e-commerce space in these geographical regions much more competitive.</p><p><blockquote>但是，一些投资者可能被Shopee（Sea Limited的电子商务部门）向新地理市场的持续扩张吓坏了。值得注意的是，Shopee继续报告每个订单调整后的EBITDA损失，如上所示。因此，一些投资者可能会担心该公司的盘子是否太大而无法处理。在过去的三个月里，该公司进入了印度、法国、西班牙和波兰等新市场。除此之外，它还在拉丁美洲，尤其是巴西与MercadoLibre(MELI)展开了战斗。因此，人们担心Sea Limited能否在亏损的同时继续在这些市场娴熟地执行任务。我们认为这种担忧是有道理的。然而，Sea Limited在渗透现有企业拥有强大领导力的最重要市场方面表现出了巨大的能力。其中包括东南亚的Lazada（BABA）、巴西的MercadoLibre和印度尼西亚的Tokopedia。Shopee从来都不是先行者。但是，它利用了“后来者”的优势，试图与现有企业竞争。值得注意的是，Sea Limited并不反对竞争。它在与现有企业的竞争中蓬勃发展，并使这些地理区域的电子商务空间更具竞争力。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/80938433e2d55307ca40000eeea2a26f\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Sea Limited revised adjusted EPS mean consensus estimates. Data source: S&amp;P Capital IQ, Seeking Alpha</span></p><p><blockquote><p class=\"t-img-caption\"><span>Sea Limited修订后的调整后每股收益均值共识估计。数据来源：S&amp;P Capital IQ、Seeking Alpha</span></p></blockquote></p><p> Nevertheless, the road towards profitability might be stretched further due to its e-commerce expansion. Readers can quickly glance over the chart above, where its adjusted EPS estimates have been revised downwards through FY23 over the last five months. However, we believe that if you are a long-term investor with a five-year horizon at least, it's not a cause for concern. Earlier investors in Sea Limited can keenly recall the company's massive adjusted EBITDA per order losses, as seen in the previous chart. Shopee has scaled tremendously over the last five years and has improved its operating leverage further. But, it's important to note that it takes time to scale up. Therefore, earlier losses in new geographical markets are expected. But, management has demonstrated its execution capability over the last three years. Considering its much reduced adjusted EBITDA losses over the previous few years, we believe that Shopee is even better positioned than before to navigate its expansion.</p><p><blockquote>然而，由于其电子商务的扩张，盈利之路可能会进一步延伸。读者可以快速浏览上图，其中2023财年在过去五个月中下调了调整后的每股收益预期。然而，我们认为，如果您是至少有五年投资期限的长期投资者，则无需担心。Sea Limited的早期投资者可以敏锐地回忆起该公司每订单调整后EBITDA的巨大损失，如上图所示。Shopee在过去五年中规模巨大，并进一步提高了其运营杠杆。但是，值得注意的是，扩大规模需要时间。因此，预计新地理市场将出现较早亏损。但是，管理层在过去三年中展示了其执行能力。考虑到过去几年调整后EBITDA亏损大幅减少，我们认为Shopee比以前更有能力应对扩张。</blockquote></p><p> <b>So, is SE Stock a Buy Now?</b></p><p><blockquote><b>那么，SE股票现在值得买入吗？</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3dbc835e49ded8a7a0e5f4fcc9e10649\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\"><span>SE stock EV/NTM Revenue 4Y mean.</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股票EV/NTM收入4年平均值。</span></p></blockquote></p><p> SE stock is trading at an EV/NTM Revenue of 8.3x. Therefore, it has brought it back to its 4Y NTM revenue multiple mean of 8.6x. We believe there's a fantastic opportunity right now as the market has undoubtedly overreacted. As demonstrated clearly, SE is still expected to generate massive revenue growth moving ahead, even though it means the road to profitability gets further extended.</p><p><blockquote>SE股票的EV/NTM收入为8.3倍。因此，它已将其恢复到4年NTM收入倍数平均值8.6倍。我们相信现在有一个绝佳的机会，因为市场无疑反应过度了。正如清楚表明的那样，SE仍有望在未来产生巨大的收入增长，尽管这意味着盈利之路将进一步延长。</blockquote></p><p> Considering its FY23 revenue estimate, SE stock is trading at just 5.8x FY23 revenue. No one can accurately predict where the stock will be headed over the next few months. But, we think it represents a tremendous opportunity right now.</p><p><blockquote>考虑到2023财年的收入预期，SE股票的交易价格仅为2023财年收入的5.8倍。没有人能够准确预测该股未来几个月的走势。但是，我们认为这现在代表着一个巨大的机会。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3bea18a0bdfd970ea640308dc35e099c\" tg-width=\"635\" tg-height=\"362\" referrerpolicy=\"no-referrer\"><span>SE stock price target Vs. actual price trend. Source: Seeking Alpha</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股价目标与实际价格趋势。资料来源：寻求阿尔法</span></p></blockquote></p><p></p><p> Moreover, readers can observe that the valuation gap between SE stock's consensus price target (PT) of $405.87 and its current price has never been more significant in a while. It's even more pronounced than its last significant correction in April/May. Notably, the consensus price target has been revised upwards despite the so-called \"gaming headwinds.\" And, if you look at the price chart, SE stock price has followed the revised PT trend very consistently over time. Therefore, the current price could be one of the most significant discounts you could observe in a long time.</p><p><blockquote>此外，读者可以观察到，SE股票405.87美元的共识目标价(PT)与其当前价格之间的估值差距从未如此显着。这甚至比4月/5月的上一次大幅调整更加明显。值得注意的是，尽管存在所谓的“博弈阻力”，但共识价格目标仍被上调。而且，如果您查看价格图表，您会发现SE股价随着时间的推移非常一致地遵循修订后的PT趋势。因此，当前价格可能是您在很长一段时间内观察到的最显着的折扣之一。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/939a544ab94c9e2a2b8a6db943703b39\" tg-width=\"910\" tg-height=\"602\" referrerpolicy=\"no-referrer\"><span>SE stock DCF valuation model. Data source: S&amp;P Capital IQ, company filings, author</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股票DCF估值模型。数据来源：S&amp;P Capital IQ，公司文件，作者</span></p></blockquote></p><p> Our DCF model also shows that SE stock is now significantly undervalued with an implied fair value of $371.46. We have also used reasonable estimates in our model. Moreover, we believe that SE will continue to gain significant operating leverage as it scales in the new markets. We estimate that its adjusted EBITDA margins could reach 15% by FY25.</p><p><blockquote>我们的DCF模型还显示，SE股票目前被严重低估，隐含公允价值为371.46美元。我们在模型中也使用了合理的估计。此外，我们相信，随着SE在新市场的扩大规模，它将继续获得巨大的运营杠杆。我们估计，到2025财年，其调整后EBITDA利润率可能达到15%。</blockquote></p><p> Lastly, the stock is also testing a critical support level that has strongly underpinned the stock's advance since early 2021. Therefore, there are sufficient reasons to believe that the current entry point to add exposure to SE stock seems very attractive now.</p><p><blockquote>最后，该股还在测试关键支撑位，该支撑位自2021年初以来有力支撑了该股的上涨。因此，有足够的理由相信，目前增加SE股票敞口的切入点现在看来非常有吸引力。</blockquote></p><p> Consequently,<i>we revise our rating on SE stock to Strong Buy</i>.</p><p><blockquote>因此，<i>我们将SE股票评级修改为强力买入</i>.</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sea Stock: Down 43% From Its High, is a Buy Now?<blockquote>Sea股票：较高点下跌43%，现在值得买入吗？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSea Stock: Down 43% From Its High, is a Buy Now?<blockquote>Sea股票：较高点下跌43%，现在值得买入吗？</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-12-20 11:55</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>Summary</b></p><p><blockquote><b>总结</b></blockquote></p><p> <ul>  <li>Sea Limited stock has been battered recently as growth stocks sold off massively in the market.</li>  <li>However, we believe that the fundamental thesis on its rapid growth remains robust.</li>  <li>We discuss why investors should capitalize on its recent significant correction to add exposure.</li> </ul> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/aa5cbe0a30acc723a2c6f62300024002\" tg-width=\"1536\" tg-height=\"1024\" referrerpolicy=\"no-referrer\"><span>kokkai/iStock Unreleased via Getty Images</span></p><p><blockquote><ul><li>由于成长型股票在市场上大量抛售，Sea Limited的股票最近遭受重创。</li><li>然而，我们认为其快速增长的基本论点仍然强劲。</li><li>我们讨论了为什么投资者应该利用其最近的重大调整来增加风险敞口。</li></ul><p class=\"t-img-caption\"><span>kokkai/iStock未通过Getty Images发布</span></p></blockquote></p><p> <b>Investment Thesis</b></p><p><blockquote><b>投资论文</b></blockquote></p><p> Sea Limited(NYSE:SE)&nbsp;stock is one of our highest conviction growth stocks that has been severely battered over the last month. Since its recent all-time high (ATH) in October, its price has dropped by a dramatic 43%. Many reasons have been presented on why the stock has fallen. We exhort investors not to read too much into them. We believe nothing material has changed from its fundamental thesis. The stock has had a remarkable run in 2021 relative to its gaming peers or e-tailer peers. Therefore, profit-taking of this extent should not be surprising as fear struck growth stocks.</p><p><blockquote>Sea Limited（纽约证券交易所股票代码：SE）股票是我们最有信心的成长型股票之一，但在上个月遭受了严重打击。自10月份创下历史新高(ATH)以来，其价格已大幅下跌43%。关于该股下跌的原因有很多。我们敦促投资者不要对他们解读太多。我们认为它的基本论点没有任何实质性的改变。相对于游戏同行或电子零售商同行，该股在2021年表现出色。因此，随着恐惧袭击成长型股票，这种程度的获利了结并不令人意外。</blockquote></p><p> Moreover, the recent significant correction in growth stocks across the market has also hit SE stock hard. But, we are not concerned. Significant volatility will always be a factor influencing the performance of growth stocks like SE in the short term.</p><p><blockquote>此外，近期全市场成长股的大幅回调也重创了SE股。但是，我们并不担心。短期内，大幅波动始终是影响SE等成长型股票表现的一个因素。</blockquote></p><p> Notably, we observed that the consensus target price on SE stock had been revised upwards since its FQ3 report card. Moreover, the gap between its price target and its current stock price has been greater than its last significant correction in April/May.</p><p><blockquote>值得注意的是，我们观察到，自第三季度成绩单以来，SE股票的共识目标价已向上修正。此外，其目标价与当前股价之间的差距已大于4月/5月的上次大幅调整。</blockquote></p><p> Our internal DCF valuation model also points to a stock that is now significantly undervalued. Thanks to the market's myopia, we have been presented with another fantastic opportunity since April/May to add SE stock with great fervor again.</p><p><blockquote>我们的内部DCF估值模型也指向一只目前被严重低估的股票。由于市场的短视，自4月/5月以来，我们又迎来了一个绝佳的机会，再次以极大的热情增持SE股票。</blockquote></p><p> We discuss why we think investors should not miss this incredible opportunity to add exposure to an outstanding growth stock.</p><p><blockquote>我们讨论了为什么我们认为投资者不应该错过这个增加对优秀成长型股票投资的绝佳机会。</blockquote></p><p> <b>SE Stock YTD Performance</b></p><p><blockquote><b>SE股票年初至今表现</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6c191d1f0f6a10e392845cdbda1264aa\" tg-width=\"640\" tg-height=\"331\" referrerpolicy=\"no-referrer\"><span>SE stock YTD performance (as of 17 December'21).</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股票年初至今表现（截至21年12月17日）。</span></p></blockquote></p><p> As a result of the significant correction recently, SE stock's YTD return has dropped to 6.9%, thus underperforming the market. Notably, its YTD gain was as high as 80% in October/early November. Despite that, the stock is still outperforming its e-tailer and gaming peers, as shown above.</p><p><blockquote>由于近期大幅调整，SE股票年初至今的回报率已降至6.9%，表现逊于大盘。值得注意的是，10月/11月初，其年初至今涨幅高达80%。尽管如此，该股的表现仍然优于电子零售商和游戏同行，如上所示。</blockquote></p><p> <b>Sea Stock Estimates Have Consistently Been Revised Upwards</b></p><p><blockquote><b>海洋库存估计不断上调</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8555128e2a30e924dd6c2dd162a27eea\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Sea Limited revised revenue mean consensus estimates. Data source: S&amp;P Capital IQ, Seeking Alpha</span></p><p><blockquote><p class=\"t-img-caption\"><span>Sea Limited修正后的收入平均共识估计。数据来源：S&amp;P Capital IQ、Seeking Alpha</span></p></blockquote></p><p> Readers can quickly observe that the company's revenue consensus estimates for FY21-23 have consistently been revised upwards over the last five months. These revisions lend credence to the robust growth prospects of the company over the next two years. Notably, Sea Limited's revenue is estimated to increase at a phenomenal CAGR of 42.8% through FY23.</p><p><blockquote>读者可以很快观察到，该公司对2021-23财年的收入共识预期在过去五个月中一直在上调。这些修正为公司未来两年的强劲增长前景增添了信心。值得注意的是，Sea Limited的收入预计将通过2023财年以42.8%的惊人复合年增长率增长。</blockquote></p><p> There were concerns over the growth rates of its Garena gaming arm in its FQ3 report card.We also explained in our previous article&nbsp;that Sea Limited has clearly explained that investors should expect normalization in Garena's growth after two spectacular years. However, its monetization capability continues to dazzle. Therefore, we are confident that Garena can continue its robust monetization strategies moving forward.</p><p><blockquote>人们对其第三季度成绩单中Garena游戏部门的增长率感到担忧。我们在上一篇文章中还解释说，Sea Limited已经明确解释说，投资者应该预计Garena的增长在经历了两年的辉煌之后将正常化。然而，其变现能力继续令人眼花缭乱。因此，我们相信Garena能够继续其稳健的货币化战略。</blockquote></p><p> Moreover, data from Sensor Tower's recent gaming statistics continue to point to sturdy performance from its Free Fire game. It continues to be ranked among the&nbsp;top ten mobile games in terms of overall gaming revenue&nbsp;in November. Moreover, it's also ranked#2 in overall downloadsacross both the App Store and Google Play. Notably, it's also among&nbsp;eight games globally whose annual revenue crossed $1B&nbsp;as of 14 December. Therefore, we think the sentiments and chatter about Free Fire's \"one-shot wonder\" have been overblown.</p><p><blockquote>此外，Sensor Tower最近的游戏统计数据继续表明其Free Fire游戏的强劲性能。继续位列11月整体游戏收入排名前十的手游。此外，它在App Store和Google Play的总下载量中也排名第二。值得注意的是，截至12月14日，它也是全球年收入超过10亿美元的八款游戏之一。因此，我们认为关于Free Fire的“一次性奇迹”的情绪和喋喋不休被夸大了。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/51247ba1efd7fa6d333b482446e94c9a\" tg-width=\"515\" tg-height=\"380\" referrerpolicy=\"no-referrer\"><span>Global games market forecast. Source: Google, Newzoo</span></p><p><blockquote><p class=\"t-img-caption\"><span>全球游戏市场预测。资料来源：谷歌、Newzoo</span></p></blockquote></p><p></p><p> In addition, the global gaming market is estimated to experience a slight decline to $175.8B after last year's massive 23% growth to $177.8B. However, given Garena's impressive growth in FY21 despite the decline in the global market, we believe it validates its business model and prospects. Notably, the gaming market is expected to reverse its decline moving forward. Therefore, Garena's leadership in mobile gaming could continue to propel its growth underpinned by the recovery in the global gaming market.</p><p><blockquote>此外，全球游戏市场在去年大幅增长23%至$177.8 B后，预计将小幅下降至$175.8 B。然而，尽管全球市场下滑，但鉴于Garena在21财年仍取得了令人印象深刻的增长，我们相信它验证了其商业模式和前景。值得注意的是，游戏市场预计将扭转未来的颓势。因此，在全球游戏市场复苏的支持下，Garena在移动游戏领域的领导地位可能会继续推动其增长。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0a0612da9a19f7b7198d43213b4f4470\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Shopee adjusted EBITDA per order. Data source: Company filings</span></p><p><blockquote><p class=\"t-img-caption\"><span>Shopee调整了每个订单的EBITDA。数据来源：公司备案</span></p></blockquote></p><p> But, some investors may have been spooked by Shopee's (Sea Limited's e-commerce arm) continued expansion into new geographical markets. Notably, Shopee continues to report adjusted EBITDA loss per order, as shown above. Therefore, some investors might have been concerned about whether the company's plate is getting too much to handle. Over the last three months, the company has entered into new markets such as India, France, Spain, and Poland. They are in addition to its battle with MercadoLibre (MELI) in Latin America, particularly Brazil. As a result, there are concerns on whether Sea Limited could continue its adroit execution in these markets while still making losses. We believe such concerns are valid. However, Sea Limited has shown its tremendous capability in penetrating the most important markets where the incumbents have strong leadership. It includes Lazada (BABA) in Southeast Asia, MercadoLibre in Brazil, and Tokopedia in Indonesia. Shopee was never the first-mover. But, it took advantage as the \"late-comer\" as it sought to compete with the incumbents. It's important to note that Sea Limited is not averse to competition. It has thrived against the incumbents and has made the e-commerce space in these geographical regions much more competitive.</p><p><blockquote>但是，一些投资者可能被Shopee（Sea Limited的电子商务部门）向新地理市场的持续扩张吓坏了。值得注意的是，Shopee继续报告每个订单调整后的EBITDA损失，如上所示。因此，一些投资者可能会担心该公司的盘子是否太大而无法处理。在过去的三个月里，该公司进入了印度、法国、西班牙和波兰等新市场。除此之外，它还在拉丁美洲，尤其是巴西与MercadoLibre(MELI)展开了战斗。因此，人们担心Sea Limited能否在亏损的同时继续在这些市场娴熟地执行任务。我们认为这种担忧是有道理的。然而，Sea Limited在渗透现有企业拥有强大领导力的最重要市场方面表现出了巨大的能力。其中包括东南亚的Lazada（BABA）、巴西的MercadoLibre和印度尼西亚的Tokopedia。Shopee从来都不是先行者。但是，它利用了“后来者”的优势，试图与现有企业竞争。值得注意的是，Sea Limited并不反对竞争。它在与现有企业的竞争中蓬勃发展，并使这些地理区域的电子商务空间更具竞争力。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/80938433e2d55307ca40000eeea2a26f\" tg-width=\"640\" tg-height=\"396\" referrerpolicy=\"no-referrer\"><span>Sea Limited revised adjusted EPS mean consensus estimates. Data source: S&amp;P Capital IQ, Seeking Alpha</span></p><p><blockquote><p class=\"t-img-caption\"><span>Sea Limited修订后的调整后每股收益均值共识估计。数据来源：S&amp;P Capital IQ、Seeking Alpha</span></p></blockquote></p><p> Nevertheless, the road towards profitability might be stretched further due to its e-commerce expansion. Readers can quickly glance over the chart above, where its adjusted EPS estimates have been revised downwards through FY23 over the last five months. However, we believe that if you are a long-term investor with a five-year horizon at least, it's not a cause for concern. Earlier investors in Sea Limited can keenly recall the company's massive adjusted EBITDA per order losses, as seen in the previous chart. Shopee has scaled tremendously over the last five years and has improved its operating leverage further. But, it's important to note that it takes time to scale up. Therefore, earlier losses in new geographical markets are expected. But, management has demonstrated its execution capability over the last three years. Considering its much reduced adjusted EBITDA losses over the previous few years, we believe that Shopee is even better positioned than before to navigate its expansion.</p><p><blockquote>然而，由于其电子商务的扩张，盈利之路可能会进一步延伸。读者可以快速浏览上图，其中2023财年在过去五个月中下调了调整后的每股收益预期。然而，我们认为，如果您是至少有五年投资期限的长期投资者，则无需担心。Sea Limited的早期投资者可以敏锐地回忆起该公司每订单调整后EBITDA的巨大损失，如上图所示。Shopee在过去五年中规模巨大，并进一步提高了其运营杠杆。但是，值得注意的是，扩大规模需要时间。因此，预计新地理市场将出现较早亏损。但是，管理层在过去三年中展示了其执行能力。考虑到过去几年调整后EBITDA亏损大幅减少，我们认为Shopee比以前更有能力应对扩张。</blockquote></p><p> <b>So, is SE Stock a Buy Now?</b></p><p><blockquote><b>那么，SE股票现在值得买入吗？</b></blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3dbc835e49ded8a7a0e5f4fcc9e10649\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\"><span>SE stock EV/NTM Revenue 4Y mean.</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股票EV/NTM收入4年平均值。</span></p></blockquote></p><p> SE stock is trading at an EV/NTM Revenue of 8.3x. Therefore, it has brought it back to its 4Y NTM revenue multiple mean of 8.6x. We believe there's a fantastic opportunity right now as the market has undoubtedly overreacted. As demonstrated clearly, SE is still expected to generate massive revenue growth moving ahead, even though it means the road to profitability gets further extended.</p><p><blockquote>SE股票的EV/NTM收入为8.3倍。因此，它已将其恢复到4年NTM收入倍数平均值8.6倍。我们相信现在有一个绝佳的机会，因为市场无疑反应过度了。正如清楚表明的那样，SE仍有望在未来产生巨大的收入增长，尽管这意味着盈利之路将进一步延长。</blockquote></p><p> Considering its FY23 revenue estimate, SE stock is trading at just 5.8x FY23 revenue. No one can accurately predict where the stock will be headed over the next few months. But, we think it represents a tremendous opportunity right now.</p><p><blockquote>考虑到2023财年的收入预期，SE股票的交易价格仅为2023财年收入的5.8倍。没有人能够准确预测该股未来几个月的走势。但是，我们认为这现在代表着一个巨大的机会。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/3bea18a0bdfd970ea640308dc35e099c\" tg-width=\"635\" tg-height=\"362\" referrerpolicy=\"no-referrer\"><span>SE stock price target Vs. actual price trend. Source: Seeking Alpha</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股价目标与实际价格趋势。资料来源：寻求阿尔法</span></p></blockquote></p><p></p><p> Moreover, readers can observe that the valuation gap between SE stock's consensus price target (PT) of $405.87 and its current price has never been more significant in a while. It's even more pronounced than its last significant correction in April/May. Notably, the consensus price target has been revised upwards despite the so-called \"gaming headwinds.\" And, if you look at the price chart, SE stock price has followed the revised PT trend very consistently over time. Therefore, the current price could be one of the most significant discounts you could observe in a long time.</p><p><blockquote>此外，读者可以观察到，SE股票405.87美元的共识目标价(PT)与其当前价格之间的估值差距从未如此显着。这甚至比4月/5月的上一次大幅调整更加明显。值得注意的是，尽管存在所谓的“博弈阻力”，但共识价格目标仍被上调。而且，如果您查看价格图表，您会发现SE股价随着时间的推移非常一致地遵循修订后的PT趋势。因此，当前价格可能是您在很长一段时间内观察到的最显着的折扣之一。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/939a544ab94c9e2a2b8a6db943703b39\" tg-width=\"910\" tg-height=\"602\" referrerpolicy=\"no-referrer\"><span>SE stock DCF valuation model. Data source: S&amp;P Capital IQ, company filings, author</span></p><p><blockquote><p class=\"t-img-caption\"><span>SE股票DCF估值模型。数据来源：S&amp;P Capital IQ，公司文件，作者</span></p></blockquote></p><p> Our DCF model also shows that SE stock is now significantly undervalued with an implied fair value of $371.46. We have also used reasonable estimates in our model. Moreover, we believe that SE will continue to gain significant operating leverage as it scales in the new markets. We estimate that its adjusted EBITDA margins could reach 15% by FY25.</p><p><blockquote>我们的DCF模型还显示，SE股票目前被严重低估，隐含公允价值为371.46美元。我们在模型中也使用了合理的估计。此外，我们相信，随着SE在新市场的扩大规模，它将继续获得巨大的运营杠杆。我们估计，到2025财年，其调整后EBITDA利润率可能达到15%。</blockquote></p><p> Lastly, the stock is also testing a critical support level that has strongly underpinned the stock's advance since early 2021. Therefore, there are sufficient reasons to believe that the current entry point to add exposure to SE stock seems very attractive now.</p><p><blockquote>最后，该股还在测试关键支撑位，该支撑位自2021年初以来有力支撑了该股的上涨。因此，有足够的理由相信，目前增加SE股票敞口的切入点现在看来非常有吸引力。</blockquote></p><p> Consequently,<i>we revise our rating on SE stock to Strong Buy</i>.</p><p><blockquote>因此，<i>我们将SE股票评级修改为强力买入</i>.</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/article/4475931-sea-se-down-significantly-stock-strong-buy\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"source_url":"https://seekingalpha.com/article/4475931-sea-se-down-significantly-stock-strong-buy","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109541249","content_text":"Summary\n\nSea Limited stock has been battered recently as growth stocks sold off massively in the market.\nHowever, we believe that the fundamental thesis on its rapid growth remains robust.\nWe discuss why investors should capitalize on its recent significant correction to add exposure.\n\nkokkai/iStock Unreleased via Getty Images\nInvestment Thesis\nSea Limited(NYSE:SE) stock is one of our highest conviction growth stocks that has been severely battered over the last month. Since its recent all-time high (ATH) in October, its price has dropped by a dramatic 43%. Many reasons have been presented on why the stock has fallen. We exhort investors not to read too much into them. We believe nothing material has changed from its fundamental thesis. The stock has had a remarkable run in 2021 relative to its gaming peers or e-tailer peers. Therefore, profit-taking of this extent should not be surprising as fear struck growth stocks.\nMoreover, the recent significant correction in growth stocks across the market has also hit SE stock hard. But, we are not concerned. Significant volatility will always be a factor influencing the performance of growth stocks like SE in the short term.\nNotably, we observed that the consensus target price on SE stock had been revised upwards since its FQ3 report card. Moreover, the gap between its price target and its current stock price has been greater than its last significant correction in April/May.\nOur internal DCF valuation model also points to a stock that is now significantly undervalued. Thanks to the market's myopia, we have been presented with another fantastic opportunity since April/May to add SE stock with great fervor again.\nWe discuss why we think investors should not miss this incredible opportunity to add exposure to an outstanding growth stock.\nSE Stock YTD Performance\nSE stock YTD performance (as of 17 December'21).\nAs a result of the significant correction recently, SE stock's YTD return has dropped to 6.9%, thus underperforming the market. Notably, its YTD gain was as high as 80% in October/early November. Despite that, the stock is still outperforming its e-tailer and gaming peers, as shown above.\nSea Stock Estimates Have Consistently Been Revised Upwards\nSea Limited revised revenue mean consensus estimates. Data source: S&P Capital IQ, Seeking Alpha\nReaders can quickly observe that the company's revenue consensus estimates for FY21-23 have consistently been revised upwards over the last five months. These revisions lend credence to the robust growth prospects of the company over the next two years. Notably, Sea Limited's revenue is estimated to increase at a phenomenal CAGR of 42.8% through FY23.\nThere were concerns over the growth rates of its Garena gaming arm in its FQ3 report card.We also explained in our previous article that Sea Limited has clearly explained that investors should expect normalization in Garena's growth after two spectacular years. However, its monetization capability continues to dazzle. Therefore, we are confident that Garena can continue its robust monetization strategies moving forward.\nMoreover, data from Sensor Tower's recent gaming statistics continue to point to sturdy performance from its Free Fire game. It continues to be ranked among the top ten mobile games in terms of overall gaming revenue in November. Moreover, it's also ranked#2 in overall downloadsacross both the App Store and Google Play. Notably, it's also among eight games globally whose annual revenue crossed $1B as of 14 December. Therefore, we think the sentiments and chatter about Free Fire's \"one-shot wonder\" have been overblown.\nGlobal games market forecast. Source: Google, Newzoo\nIn addition, the global gaming market is estimated to experience a slight decline to $175.8B after last year's massive 23% growth to $177.8B. However, given Garena's impressive growth in FY21 despite the decline in the global market, we believe it validates its business model and prospects. Notably, the gaming market is expected to reverse its decline moving forward. Therefore, Garena's leadership in mobile gaming could continue to propel its growth underpinned by the recovery in the global gaming market.\nShopee adjusted EBITDA per order. Data source: Company filings\nBut, some investors may have been spooked by Shopee's (Sea Limited's e-commerce arm) continued expansion into new geographical markets. Notably, Shopee continues to report adjusted EBITDA loss per order, as shown above. Therefore, some investors might have been concerned about whether the company's plate is getting too much to handle. Over the last three months, the company has entered into new markets such as India, France, Spain, and Poland. They are in addition to its battle with MercadoLibre (MELI) in Latin America, particularly Brazil. As a result, there are concerns on whether Sea Limited could continue its adroit execution in these markets while still making losses. We believe such concerns are valid. However, Sea Limited has shown its tremendous capability in penetrating the most important markets where the incumbents have strong leadership. It includes Lazada (BABA) in Southeast Asia, MercadoLibre in Brazil, and Tokopedia in Indonesia. Shopee was never the first-mover. But, it took advantage as the \"late-comer\" as it sought to compete with the incumbents. It's important to note that Sea Limited is not averse to competition. It has thrived against the incumbents and has made the e-commerce space in these geographical regions much more competitive.\nSea Limited revised adjusted EPS mean consensus estimates. Data source: S&P Capital IQ, Seeking Alpha\nNevertheless, the road towards profitability might be stretched further due to its e-commerce expansion. Readers can quickly glance over the chart above, where its adjusted EPS estimates have been revised downwards through FY23 over the last five months. However, we believe that if you are a long-term investor with a five-year horizon at least, it's not a cause for concern. Earlier investors in Sea Limited can keenly recall the company's massive adjusted EBITDA per order losses, as seen in the previous chart. Shopee has scaled tremendously over the last five years and has improved its operating leverage further. But, it's important to note that it takes time to scale up. Therefore, earlier losses in new geographical markets are expected. But, management has demonstrated its execution capability over the last three years. Considering its much reduced adjusted EBITDA losses over the previous few years, we believe that Shopee is even better positioned than before to navigate its expansion.\nSo, is SE Stock a Buy Now?\nSE stock EV/NTM Revenue 4Y mean.\nSE stock is trading at an EV/NTM Revenue of 8.3x. Therefore, it has brought it back to its 4Y NTM revenue multiple mean of 8.6x. We believe there's a fantastic opportunity right now as the market has undoubtedly overreacted. As demonstrated clearly, SE is still expected to generate massive revenue growth moving ahead, even though it means the road to profitability gets further extended.\nConsidering its FY23 revenue estimate, SE stock is trading at just 5.8x FY23 revenue. No one can accurately predict where the stock will be headed over the next few months. But, we think it represents a tremendous opportunity right now.\nSE stock price target Vs. actual price trend. Source: Seeking Alpha\nMoreover, readers can observe that the valuation gap between SE stock's consensus price target (PT) of $405.87 and its current price has never been more significant in a while. It's even more pronounced than its last significant correction in April/May. Notably, the consensus price target has been revised upwards despite the so-called \"gaming headwinds.\" And, if you look at the price chart, SE stock price has followed the revised PT trend very consistently over time. Therefore, the current price could be one of the most significant discounts you could observe in a long time.\nSE stock DCF valuation model. Data source: S&P Capital IQ, company filings, author\nOur DCF model also shows that SE stock is now significantly undervalued with an implied fair value of $371.46. We have also used reasonable estimates in our model. Moreover, we believe that SE will continue to gain significant operating leverage as it scales in the new markets. We estimate that its adjusted EBITDA margins could reach 15% by FY25.\nLastly, the stock is also testing a critical support level that has strongly underpinned the stock's advance since early 2021. Therefore, there are sufficient reasons to believe that the current entry point to add exposure to SE stock seems very attractive now.\nConsequently,we revise our rating on SE stock to Strong Buy.","news_type":1,"symbols_score_info":{"SE":0.9}},"isVote":1,"tweetType":1,"viewCount":2785,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699232578,"gmtCreate":1639805865423,"gmtModify":1639805865534,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"mmmm&nbsp;","listText":"mmmm&nbsp;","text":"mmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699232578","repostId":"1109831591","repostType":4,"repost":{"id":"1109831591","kind":"news","pubTimestamp":1639804463,"share":"https://www.laohu8.com/m/news/1109831591?lang=zh_CN&edition=full","pubTime":"2021-12-18 13:14","market":"us","language":"en","title":"Why Pfizer and Johnson & Johnson Fell on Friday<blockquote>辉瑞和强生周五为何下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1109831591","media":"Motley Fool","summary":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnso","content":"<p>What happened</p><p><blockquote>发生了什么</blockquote></p><p> Two prominent U.S. coronavirus stocks ended the week on a down note.&nbsp;<a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>&nbsp;and&nbsp;<a href=\"https://laohu8.com/S/JNJ\"><b>Johnson &amp; Johnson</b></a>&nbsp;both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.</p><p><blockquote>两只著名的美国冠状病毒股票本周收盘下跌。<a href=\"https://laohu8.com/S/PFE\"><b>辉瑞</b></a>和<a href=\"https://laohu8.com/S/JNJ\"><b>强生公司</b></a>当日均跌近3%。此前，一家著名投资银行对其当前前景持相当冷淡的看法。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c6a2f152eebbe10f5ab65a99815f461c\" tg-width=\"975\" tg-height=\"637\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> So what</p><p><blockquote>那又怎样</blockquote></p><p> <b>Goldman Sachs</b>&nbsp;analyst Chris Shibutani initiated coverage on Pfizer and Johnson &amp; Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.</p><p><blockquote><b>高盛</b>分析师Chris Shibutani周五开始对辉瑞和强生公司进行报道，对这两只备受瞩目的医疗保健行业股票给予中性推荐。</blockquote></p><p> Shibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech&nbsp;<b>BioNTech</b>.</p><p><blockquote>尽管辉瑞与德国生物技术公司开发的Comirnaty冠状病毒疫苗取得了巨大成功，但涩谷对他认为辉瑞的未来有些阴云密布感到担忧<b>BioNTech</b>.</blockquote></p><p> \"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.</p><p><blockquote>他写道：“我们对[辉瑞]的看法归结为，我们估计其当前估值的三分之一左右归因于COVID-19疫苗和治疗[产品]，我们认为两者的发展轨迹仍然高度不确定。”</blockquote></p><p> As for Johnson &amp; Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.</p><p><blockquote>至于强生公司，预言家认为该股的估值也相当合理。然而，他对公司的潜力持更为乐观的态度。</blockquote></p><p> \"With [Johnson &amp; Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson &amp; Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.</p><p><blockquote>“随着[强生]正处于组织多个领域的转型之中……我们看到了可能性——即使是在[强生]规模和范围的组织内——开发更多潜在的颠覆性机会在我们看来，这可能会重塑投资论点，”他写道。</blockquote></p><p> Last month, Johnson &amp; Johnson announced plans to spin off its sprawlingconsumer healthcare division.</p><p><blockquote>上个月，强生公司宣布计划剥离其庞大的消费者医疗保健部门。</blockquote></p><p> Shibutani's price target on Pfizer stock is $51 per share, and that for Johnson &amp; Johnson is $161.</p><p><blockquote>Shibutani对辉瑞股票的目标价为每股51美元，强生公司的目标价为每股161美元。</blockquote></p><p> Now what</p><p><blockquote>现在怎么办</blockquote></p><p> Pfizer and Johnson &amp; Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.</p><p><blockquote>辉瑞和强生公司无疑正在进入一些不确定的水域——无论是冠状病毒，还是后者公司显然迫在眉睫的分拆。不过，在我看来，这两家公司在各自疫苗之外的众多产品领域都拥有雄厚的实力，因此投资者不应因高盛的最新评估而过于气馁。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer and Johnson & Johnson Fell on Friday<blockquote>辉瑞和强生周五为何下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer and Johnson & Johnson Fell on Friday<blockquote>辉瑞和强生周五为何下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-12-18 13:14</span>\n</p>\n</h4>\n</header>\n<article>\n<p>What happened</p><p><blockquote>发生了什么</blockquote></p><p> Two prominent U.S. coronavirus stocks ended the week on a down note.&nbsp;<a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>&nbsp;and&nbsp;<a href=\"https://laohu8.com/S/JNJ\"><b>Johnson &amp; Johnson</b></a>&nbsp;both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.</p><p><blockquote>两只著名的美国冠状病毒股票本周收盘下跌。<a href=\"https://laohu8.com/S/PFE\"><b>辉瑞</b></a>和<a href=\"https://laohu8.com/S/JNJ\"><b>强生公司</b></a>当日均跌近3%。此前，一家著名投资银行对其当前前景持相当冷淡的看法。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c6a2f152eebbe10f5ab65a99815f461c\" tg-width=\"975\" tg-height=\"637\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> So what</p><p><blockquote>那又怎样</blockquote></p><p> <b>Goldman Sachs</b>&nbsp;analyst Chris Shibutani initiated coverage on Pfizer and Johnson &amp; Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.</p><p><blockquote><b>高盛</b>分析师Chris Shibutani周五开始对辉瑞和强生公司进行报道，对这两只备受瞩目的医疗保健行业股票给予中性推荐。</blockquote></p><p> Shibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech&nbsp;<b>BioNTech</b>.</p><p><blockquote>尽管辉瑞与德国生物技术公司开发的Comirnaty冠状病毒疫苗取得了巨大成功，但涩谷对他认为辉瑞的未来有些阴云密布感到担忧<b>BioNTech</b>.</blockquote></p><p> \"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.</p><p><blockquote>他写道：“我们对[辉瑞]的看法归结为，我们估计其当前估值的三分之一左右归因于COVID-19疫苗和治疗[产品]，我们认为两者的发展轨迹仍然高度不确定。”</blockquote></p><p> As for Johnson &amp; Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.</p><p><blockquote>至于强生公司，预言家认为该股的估值也相当合理。然而，他对公司的潜力持更为乐观的态度。</blockquote></p><p> \"With [Johnson &amp; Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson &amp; Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.</p><p><blockquote>“随着[强生]正处于组织多个领域的转型之中……我们看到了可能性——即使是在[强生]规模和范围的组织内——开发更多潜在的颠覆性机会在我们看来，这可能会重塑投资论点，”他写道。</blockquote></p><p> Last month, Johnson &amp; Johnson announced plans to spin off its sprawlingconsumer healthcare division.</p><p><blockquote>上个月，强生公司宣布计划剥离其庞大的消费者医疗保健部门。</blockquote></p><p> Shibutani's price target on Pfizer stock is $51 per share, and that for Johnson &amp; Johnson is $161.</p><p><blockquote>Shibutani对辉瑞股票的目标价为每股51美元，强生公司的目标价为每股161美元。</blockquote></p><p> Now what</p><p><blockquote>现在怎么办</blockquote></p><p> Pfizer and Johnson &amp; Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.</p><p><blockquote>辉瑞和强生公司无疑正在进入一些不确定的水域——无论是冠状病毒，还是后者公司显然迫在眉睫的分拆。不过，在我看来，这两家公司在各自疫苗之外的众多产品领域都拥有雄厚的实力，因此投资者不应因高盛的最新评估而过于气馁。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109831591","content_text":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnson & Johnson both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.\n\nSo what\nGoldman Sachs analyst Chris Shibutani initiated coverage on Pfizer and Johnson & Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.\nShibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech BioNTech.\n\"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.\nAs for Johnson & Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.\n\"With [Johnson & Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson & Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.\nLast month, Johnson & Johnson announced plans to spin off its sprawlingconsumer healthcare division.\nShibutani's price target on Pfizer stock is $51 per share, and that for Johnson & Johnson is $161.\nNow what\nPfizer and Johnson & Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.","news_type":1,"symbols_score_info":{"PFE":0.9,"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":2606,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699238053,"gmtCreate":1639805119710,"gmtModify":1639805119710,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"buy at dip?&nbsp;[Cool]&nbsp;","listText":"buy at dip?&nbsp;[Cool]&nbsp;","text":"buy at dip? [Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699238053","repostId":"1113352768","repostType":4,"repost":{"id":"1113352768","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639752492,"share":"https://www.laohu8.com/m/news/1113352768?lang=zh_CN&edition=full","pubTime":"2021-12-17 22:48","market":"us","language":"en","title":"Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group<blockquote>由于印度暂停2019年与Future Group的交易，亚马逊早盘下跌近2%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1113352768","media":"Tiger Newspress","summary":"Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group.India's ","content":"<p>Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group.<img src=\"https://static.tigerbbs.com/ecaa54686b8d8b0541b8769a2aa237a3\" tg-width=\"766\" tg-height=\"567\" width=\"100%\" height=\"auto\">India's antitrust body on Friday suspended Amazon.com's 2019 deal with Future Group following a review of allegations that the U.S. e-commerce giant had concealed information while seeking regulatory approval.</p><p><blockquote>由于印度暂停2019年与Future Group的交易，亚马逊早盘下跌近2%。印度反垄断机构周五暂停了亚马逊2019年与Future Group的交易，此前印度对这家美国电子商务巨头在寻求监管机构批准时隐瞒信息的指控进行了审查。</blockquote></p><p> The unprecedented step taken by the Competition Commission of India (CCI) could have far-reaching consequences on Amazon's legal battles with now estranged partner Future. The U.S. firm has for months successfully used the terms of its toehold $200 million investment in 2019 to block Future's attempt to sell retail assets to Reliance Industries for $3.4 billion.</p><p><blockquote>印度（CCI）竞争委员会采取的前所未有的举措可能会对亚马逊与现已疏远的合作伙伴Future的法律斗争产生深远的影响。几个月来，这家美国公司成功利用其2019年2亿美元投资的条款，阻止了Future以34亿美元的价格向Reliance Industries出售零售资产的企图。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group<blockquote>由于印度暂停2019年与Future Group的交易，亚马逊早盘下跌近2%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group<blockquote>由于印度暂停2019年与Future Group的交易，亚马逊早盘下跌近2%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-17 22:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group.<img src=\"https://static.tigerbbs.com/ecaa54686b8d8b0541b8769a2aa237a3\" tg-width=\"766\" tg-height=\"567\" width=\"100%\" height=\"auto\">India's antitrust body on Friday suspended Amazon.com's 2019 deal with Future Group following a review of allegations that the U.S. e-commerce giant had concealed information while seeking regulatory approval.</p><p><blockquote>由于印度暂停2019年与Future Group的交易，亚马逊早盘下跌近2%。印度反垄断机构周五暂停了亚马逊2019年与Future Group的交易，此前印度对这家美国电子商务巨头在寻求监管机构批准时隐瞒信息的指控进行了审查。</blockquote></p><p> The unprecedented step taken by the Competition Commission of India (CCI) could have far-reaching consequences on Amazon's legal battles with now estranged partner Future. The U.S. firm has for months successfully used the terms of its toehold $200 million investment in 2019 to block Future's attempt to sell retail assets to Reliance Industries for $3.4 billion.</p><p><blockquote>印度（CCI）竞争委员会采取的前所未有的举措可能会对亚马逊与现已疏远的合作伙伴Future的法律斗争产生深远的影响。几个月来，这家美国公司成功利用其2019年2亿美元投资的条款，阻止了Future以34亿美元的价格向Reliance Industries出售零售资产的企图。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113352768","content_text":"Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group.India's antitrust body on Friday suspended Amazon.com's 2019 deal with Future Group following a review of allegations that the U.S. e-commerce giant had concealed information while seeking regulatory approval.\nThe unprecedented step taken by the Competition Commission of India (CCI) could have far-reaching consequences on Amazon's legal battles with now estranged partner Future. The U.S. firm has for months successfully used the terms of its toehold $200 million investment in 2019 to block Future's attempt to sell retail assets to Reliance Industries for $3.4 billion.","news_type":1,"symbols_score_info":{"AMZN":0.9}},"isVote":1,"tweetType":1,"viewCount":2284,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602453657,"gmtCreate":1639060563339,"gmtModify":1639061378393,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"very insightful article and shed some light on why&nbsp;<a href=\"https://laohu8.com/S/GRAB\">$Grab Holdings(GRAB)$</a>is doing so badly. only wish it came out earlier&nbsp;[Cry]&nbsp;","listText":"very insightful article and shed some light on why&nbsp;<a href=\"https://laohu8.com/S/GRAB\">$Grab Holdings(GRAB)$</a>is doing so badly. only wish it came out earlier&nbsp;[Cry]&nbsp;","text":"very insightful article and shed some light on why $Grab Holdings(GRAB)$is doing so badly. only wish it came out earlier [Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602453657","repostId":"2190614747","repostType":2,"isVote":1,"tweetType":1,"viewCount":4599,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602468206,"gmtCreate":1639058758922,"gmtModify":1639059675097,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"wanted to buy the dip but there isn't really a dip with&nbsp;[LOL]&nbsp;","listText":"wanted to buy the dip but there isn't really a dip with&nbsp;[LOL]&nbsp;","text":"wanted to buy the dip but there isn't really a dip with [LOL]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602468206","repostId":"1129645066","repostType":4,"repost":{"id":"1129645066","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639053071,"share":"https://www.laohu8.com/m/news/1129645066?lang=zh_CN&edition=full","pubTime":"2021-12-09 20:31","market":"us","language":"en","title":"Amazon shares fell slightly by 0.5% in premarket trading<blockquote>亚马逊股价在盘前交易中小幅下跌0.5%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1129645066","media":"Tiger Newspress","summary":"Amazon shares fell slightly by 0.5% in premarket trading after Italy's antitrust fined Amazon 1.13 b","content":"<p>Amazon shares fell slightly by 0.5% in premarket trading&nbsp;after&nbsp;Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.</p><p><blockquote>意大利反垄断机构因亚马逊涉嫌滥用市场支配地位对其处以11.3亿欧元罚款，亚马逊股价在盘前交易中小幅下跌0.5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1aa0616746882964f5e05a784287edeb\" tg-width=\"850\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Italy's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.</p><p><blockquote>意大利反垄断机构周四表示，已对电商巨头亚马逊处以11.3亿欧元（12.8亿美元）的罚款，原因是其涉嫌滥用市场支配地位。</blockquote></p><p> In a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.</p><p><blockquote>该监管机构在一份声明中表示，亚马逊损害了电子商务物流服务领域的竞争运营商。</blockquote></p><p> \"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.</p><p><blockquote>“亚马逊在意大利市场中介服务市场上占据主导地位，亚马逊利用这一优势鼓励活跃在Amazon.it上的卖家采用自己的物流服务——亚马逊物流(FBA)，从而损害了竞争运营商提供的物流服务，并加强其自身的主导地位，”它补充道。</blockquote></p><p> The antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.</p><p><blockquote>反垄断机构表示，将对亚马逊采取纠正措施，这些措施将接受监督受托人的审查。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon shares fell slightly by 0.5% in premarket trading<blockquote>亚马逊股价在盘前交易中小幅下跌0.5%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon shares fell slightly by 0.5% in premarket trading<blockquote>亚马逊股价在盘前交易中小幅下跌0.5%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-09 20:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Amazon shares fell slightly by 0.5% in premarket trading&nbsp;after&nbsp;Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.</p><p><blockquote>意大利反垄断机构因亚马逊涉嫌滥用市场支配地位对其处以11.3亿欧元罚款，亚马逊股价在盘前交易中小幅下跌0.5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1aa0616746882964f5e05a784287edeb\" tg-width=\"850\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Italy's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.</p><p><blockquote>意大利反垄断机构周四表示，已对电商巨头亚马逊处以11.3亿欧元（12.8亿美元）的罚款，原因是其涉嫌滥用市场支配地位。</blockquote></p><p> In a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.</p><p><blockquote>该监管机构在一份声明中表示，亚马逊损害了电子商务物流服务领域的竞争运营商。</blockquote></p><p> \"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.</p><p><blockquote>“亚马逊在意大利市场中介服务市场上占据主导地位，亚马逊利用这一优势鼓励活跃在Amazon.it上的卖家采用自己的物流服务——亚马逊物流(FBA)，从而损害了竞争运营商提供的物流服务，并加强其自身的主导地位，”它补充道。</blockquote></p><p> The antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.</p><p><blockquote>反垄断机构表示，将对亚马逊采取纠正措施，这些措施将接受监督受托人的审查。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129645066","content_text":"Amazon shares fell slightly by 0.5% in premarket trading after Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.\n\nItaly's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.\nIn a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.\n\"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.\nThe antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.","news_type":1,"symbols_score_info":{"AMZN":0.9}},"isVote":1,"tweetType":1,"viewCount":2996,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602132570,"gmtCreate":1638979550717,"gmtModify":1638979550717,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"to the moon!&nbsp;[Cool]&nbsp;[Cool]&nbsp;","listText":"to the moon!&nbsp;[Cool]&nbsp;[Cool]&nbsp;","text":"to the moon! [Cool] [Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602132570","repostId":"1161444269","repostType":4,"repost":{"id":"1161444269","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638977215,"share":"https://www.laohu8.com/m/news/1161444269?lang=zh_CN&edition=full","pubTime":"2021-12-08 23:26","market":"us","language":"en","title":"Apple shares rose nearly 2% to a new high<blockquote>苹果股价上涨近2%，创新高</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1161444269","media":"Tiger Newspress","summary":"Apple shares rose nearly 2% to a new high in morning trading.","content":"<p>Apple shares rose nearly 2% to a new high&nbsp;in morning trading.</p><p><blockquote>苹果股价在早盘交易中上涨近2%，创下新高。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/9a9f5fdc1cb0a898675c515a39de7611\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple shares rose nearly 2% to a new high<blockquote>苹果股价上涨近2%，创新高</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple shares rose nearly 2% to a new high<blockquote>苹果股价上涨近2%，创新高</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-08 23:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Apple shares rose nearly 2% to a new high&nbsp;in morning trading.</p><p><blockquote>苹果股价在早盘交易中上涨近2%，创下新高。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/9a9f5fdc1cb0a898675c515a39de7611\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161444269","content_text":"Apple shares rose nearly 2% to a new high in morning trading.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":3489,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602136955,"gmtCreate":1638979419776,"gmtModify":1638979419884,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602136955","repostId":"1177589023","repostType":4,"repost":{"id":"1177589023","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638964838,"share":"https://www.laohu8.com/m/news/1177589023?lang=zh_CN&edition=full","pubTime":"2021-12-08 20:00","market":"us","language":"en","title":"Pfizer, BioNTech say third dose neutralizes Omicron variant<blockquote>辉瑞和BioNTech表示第三剂疫苗可以中和奥密克戎病毒变种</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1177589023","media":"Tiger Newspress","summary":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on ","content":"<p>Pfizer and biontech stocks narrowed their losses&nbsp;in premarket trading&nbsp;after&nbsp;they provided update on Omicron variant.</p><p><blockquote>辉瑞和biontech股票在提供奥密克戎变种的最新信息后，在盘前交易中收窄了跌幅。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <ul>  <li><i>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</i></li>  <li><i>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</i></li>  <li><i>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</i></li>  <li><i>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</i></li> </ul> Pfizer Inc.&nbsp;and&nbsp;BioNTech SE&nbsp;today announced results from an initial&nbsp;<i>laboratory</i>&nbsp;study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.</p><p><blockquote><ul><li><i>初步实验室研究表明，三剂辉瑞-BioNTech新冠肺炎疫苗中和了奥密克戎变异体（B.1.1.529谱系），而两剂显示中和滴度显著降低</i></li><li><i>数据表明，与针对奥密克戎变体的两个剂量相比，第三个剂量的BNT162b2使中和抗体滴度增加了25倍；加强剂量后的滴度与针对野生型病毒的两次剂量后观察到的滴度相当，其与高水平的保护相关</i></li><li><i>由于CD8+T细胞识别的刺突蛋白中80%的表位不受奥密克戎变异体突变的影响，两次剂量仍可能诱导对严重疾病的保护</i></li><li><i>两家公司继续推进针对奥密克戎病毒的变异特异性疫苗的开发，预计如果需要进行调整以进一步提高保护水平和持续时间，将在3月份之前上市-预计两家公司的疫苗不会发生变化2022年40亿剂产能</i></li></ul>辉瑞公司和BioNTech SE今天公布了初步结果<i>实验室</i>研究表明，辉瑞-BioNTech新冠肺炎疫苗（BNT162b2）诱导的血清抗体在三剂后中和新型冠状病毒奥密克戎变异体。在接受加强疫苗接种（第三剂BNT162b2疫苗）后一个月从接种者获得的血清中和了奥密克戎变异体，其水平与两剂后观察到的野生型新型冠状病毒刺突蛋白相当。</blockquote></p><p> Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.</p><p><blockquote>与野生型相比，接受两剂当前新冠肺炎疫苗的个体的血清对奥密克戎变异体的中和滴度平均降低了25倍以上，这表明两剂BNT162b2可能不足以预防奥密克戎变异体的感染。然而，由于疫苗诱导的T细胞靶向的绝大多数表位不受奥密克戎病突变的影响，两家公司认为，接种疫苗的个体可能仍然可以预防严重形式的疾病，并正在密切监测全球范围内针对奥密克戎的真实有效性。</blockquote></p><p> A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.</p><p><blockquote>第三剂可以实现更强大的保护，因为两家公司的其他研究数据表明，辉瑞和BioNTech的当前新冠肺炎疫苗的加强剂可以将抗体滴度提高25倍。根据两家公司的初步数据，第三剂疫苗提供的奥密克戎中和抗体水平与针对野生型和奥密克戎之前出现的其他变种的两剂疫苗后观察到的相似。这些抗体水平与针对野生型病毒和这些变体两者的高功效相关。第三剂量还强烈增加针对多个刺突蛋白表位的CD8+T细胞水平，所述多个刺突蛋白表位被认为与针对严重疾病的保护相关。与野生型病毒相比，这些表位中的绝大多数在奥密克戎刺突变体中保持不变。</blockquote></p><p> “Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said&nbsp;<b>Albert Bourla, Chairman and Chief Executive Officer, Pfizer</b>. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”</p><p><blockquote>“虽然两剂疫苗可能仍然可以预防由奥密克戎毒株引起的严重疾病，但从这些初步数据可以清楚地看出，第三剂我们的疫苗可以提高保护作用，”他说。<b>Albert Bourla，辉瑞公司董事长兼首席执行官</b>.“确保尽可能多的人完全接种前两剂系列疫苗和加强剂仍然是防止COVID-19传播的最佳行动方案。”</blockquote></p><p> “Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said&nbsp;<b>Ugur Sahin, M.D., CEO and Co-Founder of BioNTech</b>. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”</p><p><blockquote>“我们的初步、第一个数据集表明，第三剂疫苗仍然可以提供足够的保护，预防由奥密克戎变种引起的任何严重程度的疾病，”他说。<b>Ugur Sahin，医学博士，BioNTech首席执行官兼联合创始人</b>“世界各地广泛的疫苗接种和加强疫苗接种活动可以帮助我们更好地保护世界各地的人们并度过冬季。我们继续研究一种适应性疫苗，我们相信这将有助于诱导针对奥密克戎引起的COVID-19疾病的高水平保护，与目前的疫苗相比，保护时间更长。”</blockquote></p><p></p><p> While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta &amp; Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.</p><p><blockquote>虽然这些结果是初步的，但两家公司将继续收集更多的实验室数据并评估现实世界的有效性，以评估和确认对奥密克戎的保护，并为最有效的前进道路提供信息。11月25日，两家公司开始开发一种针对奥密克戎的COVID-19疫苗。如果需要调整疫苗以提高对奥密克戎的保护水平和持续时间，开发将按计划继续进行。第一批基于奥密克戎的疫苗可以生产，并计划在100天内准备好交付，等待监管部门的批准。辉瑞和BioNTech也测试了其他变异特异性疫苗，这些疫苗产生了非常强的中和滴度和可耐受的安全性。基于这一经验，这些公司非常有信心，如果需要，他们可以在2022年3月交付基于奥密克戎的疫苗。这些公司此前还启动了变异特异性疫苗（Alpha、Beta、Delta和Alpha/Delta Mix）的临床试验，这些研究的数据将提交给世界各地的监管机构，以帮助加快适应疫苗的过程，并在需要时获得奥密克戎特异性疫苗的监管授权或批准。两家公司此前曾宣布，他们预计在2022年生产40亿剂BNT162b2，如果需要适应的疫苗，预计这一产能不会改变。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, BioNTech say third dose neutralizes Omicron variant<blockquote>辉瑞和BioNTech表示第三剂疫苗可以中和奥密克戎病毒变种</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, BioNTech say third dose neutralizes Omicron variant<blockquote>辉瑞和BioNTech表示第三剂疫苗可以中和奥密克戎病毒变种</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-08 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Pfizer and biontech stocks narrowed their losses&nbsp;in premarket trading&nbsp;after&nbsp;they provided update on Omicron variant.</p><p><blockquote>辉瑞和biontech股票在提供奥密克戎变种的最新信息后，在盘前交易中收窄了跌幅。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/896ce4e657b0942d9d7a0abce1c3d2f7\" tg-width=\"853\" tg-height=\"622\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/35c4bf42aa2936640aedd52e01beebc5\" tg-width=\"853\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <ul>  <li><i>Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers</i></li>  <li><i>Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection</i></li>  <li><i>As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease</i></li>  <li><i>The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022</i></li> </ul> Pfizer Inc.&nbsp;and&nbsp;BioNTech SE&nbsp;today announced results from an initial&nbsp;<i>laboratory</i>&nbsp;study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.</p><p><blockquote><ul><li><i>初步实验室研究表明，三剂辉瑞-BioNTech新冠肺炎疫苗中和了奥密克戎变异体（B.1.1.529谱系），而两剂显示中和滴度显著降低</i></li><li><i>数据表明，与针对奥密克戎变体的两个剂量相比，第三个剂量的BNT162b2使中和抗体滴度增加了25倍；加强剂量后的滴度与针对野生型病毒的两次剂量后观察到的滴度相当，其与高水平的保护相关</i></li><li><i>由于CD8+T细胞识别的刺突蛋白中80%的表位不受奥密克戎变异体突变的影响，两次剂量仍可能诱导对严重疾病的保护</i></li><li><i>两家公司继续推进针对奥密克戎病毒的变异特异性疫苗的开发，预计如果需要进行调整以进一步提高保护水平和持续时间，将在3月份之前上市-预计两家公司的疫苗不会发生变化2022年40亿剂产能</i></li></ul>辉瑞公司和BioNTech SE今天公布了初步结果<i>实验室</i>研究表明，辉瑞-BioNTech新冠肺炎疫苗（BNT162b2）诱导的血清抗体在三剂后中和新型冠状病毒奥密克戎变异体。在接受加强疫苗接种（第三剂BNT162b2疫苗）后一个月从接种者获得的血清中和了奥密克戎变异体，其水平与两剂后观察到的野生型新型冠状病毒刺突蛋白相当。</blockquote></p><p> Sera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.</p><p><blockquote>与野生型相比，接受两剂当前新冠肺炎疫苗的个体的血清对奥密克戎变异体的中和滴度平均降低了25倍以上，这表明两剂BNT162b2可能不足以预防奥密克戎变异体的感染。然而，由于疫苗诱导的T细胞靶向的绝大多数表位不受奥密克戎病突变的影响，两家公司认为，接种疫苗的个体可能仍然可以预防严重形式的疾病，并正在密切监测全球范围内针对奥密克戎的真实有效性。</blockquote></p><p> A more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.</p><p><blockquote>第三剂可以实现更强大的保护，因为两家公司的其他研究数据表明，辉瑞和BioNTech的当前新冠肺炎疫苗的加强剂可以将抗体滴度提高25倍。根据两家公司的初步数据，第三剂疫苗提供的奥密克戎中和抗体水平与针对野生型和奥密克戎之前出现的其他变种的两剂疫苗后观察到的相似。这些抗体水平与针对野生型病毒和这些变体两者的高功效相关。第三剂量还强烈增加针对多个刺突蛋白表位的CD8+T细胞水平，所述多个刺突蛋白表位被认为与针对严重疾病的保护相关。与野生型病毒相比，这些表位中的绝大多数在奥密克戎刺突变体中保持不变。</blockquote></p><p> “Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said&nbsp;<b>Albert Bourla, Chairman and Chief Executive Officer, Pfizer</b>. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”</p><p><blockquote>“虽然两剂疫苗可能仍然可以预防由奥密克戎毒株引起的严重疾病，但从这些初步数据可以清楚地看出，第三剂我们的疫苗可以提高保护作用，”他说。<b>Albert Bourla，辉瑞公司董事长兼首席执行官</b>.“确保尽可能多的人完全接种前两剂系列疫苗和加强剂仍然是防止COVID-19传播的最佳行动方案。”</blockquote></p><p> “Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said&nbsp;<b>Ugur Sahin, M.D., CEO and Co-Founder of BioNTech</b>. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”</p><p><blockquote>“我们的初步、第一个数据集表明，第三剂疫苗仍然可以提供足够的保护，预防由奥密克戎变种引起的任何严重程度的疾病，”他说。<b>Ugur Sahin，医学博士，BioNTech首席执行官兼联合创始人</b>“世界各地广泛的疫苗接种和加强疫苗接种活动可以帮助我们更好地保护世界各地的人们并度过冬季。我们继续研究一种适应性疫苗，我们相信这将有助于诱导针对奥密克戎引起的COVID-19疾病的高水平保护，与目前的疫苗相比，保护时间更长。”</blockquote></p><p></p><p> While these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta &amp; Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.</p><p><blockquote>虽然这些结果是初步的，但两家公司将继续收集更多的实验室数据并评估现实世界的有效性，以评估和确认对奥密克戎的保护，并为最有效的前进道路提供信息。11月25日，两家公司开始开发一种针对奥密克戎的COVID-19疫苗。如果需要调整疫苗以提高对奥密克戎的保护水平和持续时间，开发将按计划继续进行。第一批基于奥密克戎的疫苗可以生产，并计划在100天内准备好交付，等待监管部门的批准。辉瑞和BioNTech也测试了其他变异特异性疫苗，这些疫苗产生了非常强的中和滴度和可耐受的安全性。基于这一经验，这些公司非常有信心，如果需要，他们可以在2022年3月交付基于奥密克戎的疫苗。这些公司此前还启动了变异特异性疫苗（Alpha、Beta、Delta和Alpha/Delta Mix）的临床试验，这些研究的数据将提交给世界各地的监管机构，以帮助加快适应疫苗的过程，并在需要时获得奥密克戎特异性疫苗的监管授权或批准。两家公司此前曾宣布，他们预计在2022年生产40亿剂BNT162b2，如果需要适应的疫苗，预计这一产能不会改变。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177589023","content_text":"Pfizer and biontech stocks narrowed their losses in premarket trading after they provided update on Omicron variant.\n\n\nPreliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers\nData indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection\nAs 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease\nThe companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022\n\nPfizer Inc. and BioNTech SE today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) neutralize the SARS-CoV-2 Omicron variant after three doses. Sera obtained from vaccinees one month after receiving the booster vaccination (third dose of BNT162b2 vaccine) neutralized the Omicron variant to levels that are comparable to thoseobserved for the wild-type SARS-CoV-2 spike protein after two doses.\nSera from individuals who received two doses of the current COVID-19 vaccine did exhibit, on average, more than a 25-fold reduction in neutralization titers against the Omicron variant compared to wild-type, indicating that two doses of BNT162b2 may not be sufficient to protect against infection with the Omicron variant. However, as the vast majority of epitopes targeted by vaccine-induced T cells are not affected by the mutations in Omicron, the companies believe that vaccinated individuals may still be protected against severe forms of the disease and are closely monitoring real world effectiveness against Omicron, globally.\nA more robust protection may be achieved by a third dose as data from additional studies of the companies indicate that a booster with the current COVID-19 vaccine from Pfizer and BioNTech increases the antibody titers by 25-fold. According to the companies’ preliminary data, a third dose provides a similar level of neutralizing antibodies to Omicron as is observed after two doses against wild-type and other variants that emerged before Omicron. These antibody levels are associated with high efficacy against both the wild-type virus and these variants. A third dose also strongly increases CD8+T cell levels against multiple spike protein epitopes which are considered to correlate with the protection against severe disease. Compared to the wild-type virus, the vast majority of these epitopes remain unchanged in the Omicron spike variant.\n“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is improved with a third dose of our vaccine,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.”\n“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” said Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “Broad vaccination and booster campaigns around the world could help us to better protect people everywhere and to get through the winter season. We continue to work on an adapted vaccine which, we believe, will help to induce a high level of protection against Omicron-induced COVID-19 disease as well as a prolonged protection compared to the current vaccine.”\nWhile these results are preliminary, the companies will continue to collect more laboratory data and evaluate real-world effectiveness to assess and confirm protection against Omicron and inform the most effective path forward. On November 25, the companies started to develop an Omicron-specific COVID-19 vaccine. The development will continue as planned in the event that a vaccine adaption is needed to increase the level and duration of protection against Omicron. First batches of the Omicron-based vaccine can be produced and are planned to be ready for deliveries within 100 days, pending regulatory approval. Pfizer and BioNTech have tested other variant-specific vaccines as well, which have produced very strong neutralization titers and a tolerable safety profile. Based on this experience the companies have high confidence that if needed they can deliver an Omicron-based vaccine in March 2022. The companies have also previously initiated clinical trials with variant-specific vaccines (Alpha, Beta, Delta & Alpha/Delta Mix) and data from these studies will be submitted to regulatory agencies around the world to help accelerate the process of adapting the vaccine and gaining regulatory authorization or approval of an Omicron-specific vaccine, if needed. The companies have previously announced that they expect to produce four billion doses of BNT162b2 in 2022, and this capacity is not expected to change if an adapted vaccine is required.","news_type":1,"symbols_score_info":{"BNTX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2632,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603647269,"gmtCreate":1638408688437,"gmtModify":1638413365848,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"It's really interesting to note that&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>is clearly needed worldwide but yet its share is still&nbsp;[Speechless]&nbsp;[Speechless]&nbsp;","listText":"It's really interesting to note that&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>is clearly needed worldwide but yet its share is still&nbsp;[Speechless]&nbsp;[Speechless]&nbsp;","text":"It's really interesting to note that $Moderna, Inc.(MRNA)$is clearly needed worldwide but yet its share is still [Speechless] [Speechless]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603647269","repostId":"2188560153","repostType":2,"isVote":1,"tweetType":1,"viewCount":2439,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603132509,"gmtCreate":1638372243529,"gmtModify":1638372243668,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"A good time to buy in&nbsp;<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>[Cool]&nbsp;","listText":"A good time to buy in&nbsp;<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>[Cool]&nbsp;","text":"A good time to buy in $Sea Ltd(SE)$[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603132509","repostId":"2186310769","repostType":2,"isVote":1,"tweetType":1,"viewCount":3260,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600550505,"gmtCreate":1638177679665,"gmtModify":1638177748090,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"[财迷]&nbsp;","listText":"[财迷]&nbsp;","text":"[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600550505","repostId":"1106015985","repostType":2,"repost":{"id":"1106015985","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638176514,"share":"https://www.laohu8.com/m/news/1106015985?lang=zh_CN&edition=full","pubTime":"2021-11-29 17:01","market":"us","language":"en","title":"Moderna stock surged 8% in premarket trading<blockquote>Moderna股价在盘前交易中飙升8%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1106015985","media":"Tiger Newspress","summary":"Moderna stock surged 8% in premarket trading as it said new covid-19 vaccine for Omicron might be re","content":"<p>Moderna stock surged 8% in premarket trading&nbsp;as&nbsp;it&nbsp;said new covid-19 vaccine for Omicron might be ready in early 2022.</p><p><blockquote>Moderna股价在盘前交易中飙升8%，因为该公司表示，针对奥密克戎的新covid-19疫苗可能会在2022年初准备就绪。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/660e8ece7a2b338498e4bfe9f3c38228\" tg-width=\"851\" tg-height=\"616\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Moderna&nbsp;chief medical officer Paul Burton said he suspects the new Omicron coronavirus variant may elude current vaccines, and if so, a reformulated shot could be available early in the new year.</p><p><blockquote>Moderna首席医疗官保罗·伯顿(Paul Burton)表示，他怀疑新的奥密克戎冠状病毒变种可能会躲避目前的疫苗，如果是这样，重新配制的疫苗可能会在新年伊始上市。</blockquote></p><p> \"We should know about the ability of the current vaccine to provide protection in the next couple of weeks,\" Mr Burton said on Sunday (Nov 28) on the BBC's Andrew Marr Show.</p><p><blockquote>伯顿周日（11月28日）在BBC的安德鲁·马尔节目中表示：“我们应该了解当前疫苗在未来几周内提供保护的能力。”</blockquote></p><p> \"If we have to make a brand new vaccine, I think that's going to be early 2022 before that's really going to be available in large quantities,\" he said.</p><p><blockquote>“如果我们必须制造一种全新的疫苗，我认为要到2022年初才能真正大量上市，”他说。</blockquote></p><p> \"The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast,\" he added.</p><p><blockquote>“mRNA疫苗Moderna平台的非凡之处在于我们可以非常快地行动，”他补充道。</blockquote></p><p> The Cambridge, Massachusetts-based biotech company mobilised \"hundreds\" of staff early last&nbsp;Thursday, Thanksgiving Day in the United States, after news of the Omicron variant spread.</p><p><blockquote>在奥密克戎变种病毒的消息传开后，这家总部位于麻省剑桥的生物技术公司于上周四美国感恩节早些时候动员了“数百名”员工。</blockquote></p><p> Protection should still exist, depending on how long ago a person was vaccinated, and for now the best advice is to take one of the current Covid-19 vaccines, Mr Burton said.</p><p><blockquote>伯顿先生说，保护应该仍然存在，这取决于一个人多久前接种疫苗，目前最好的建议是接种一种当前的新冠肺炎疫苗。</blockquote></p><p> \"If people are on the fence, and you haven't been vaccinated, get vaccinated,\" he said. \"This is a dangerous-looking virus, but I think we have many tools in our armamentarium now to fight it.\"</p><p><blockquote>“如果人们持观望态度，而你还没有接种疫苗，那就接种疫苗，”他说。“这是一种看起来很危险的病毒，但我认为我们现在的医疗设备中有很多工具来对抗它。”</blockquote></p><p> The emergence of the Omicron strain has seen countries rush to clamp down on travel from southern Africa.</p><p><blockquote>奥密克戎病毒株的出现导致各国急于限制来自南部非洲的旅行。</blockquote></p><p> Fears that it could exacerbate a winter Covid-19 surge in the northern hemisphere and undermine a global economic recovery sent a wave of risk aversion across global markets last&nbsp;Friday that continued on Sunday when the Middle East opened for the week.</p><p><blockquote>由于担心这可能会加剧北半球冬季Covid-19激增并破坏全球经济复苏，上周五全球市场掀起了一波避险浪潮，并在周日中东本周开盘时持续。</blockquote></p><p> Moderna said in a release on Friday that it was working rapidly to test the current vaccine against the Omicron variant, and studying two booster candidates.</p><p><blockquote>Moderna在周五的一份新闻稿中表示，它正在迅速测试目前针对奥密克戎变种的疫苗，并研究两种候选加强剂。</blockquote></p><p> \"Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern,\" the company said. \"The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60 to 90 days.\"</p><p><blockquote>该公司表示：“自2021年初以来，Moderna制定了一项全面的战略，以预测令人担忧的新变种。”“该公司已多次证明有能力在60至90天内将新候选药物推进临床测试。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock surged 8% in premarket trading<blockquote>Moderna股价在盘前交易中飙升8%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock surged 8% in premarket trading<blockquote>Moderna股价在盘前交易中飙升8%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-29 17:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock surged 8% in premarket trading&nbsp;as&nbsp;it&nbsp;said new covid-19 vaccine for Omicron might be ready in early 2022.</p><p><blockquote>Moderna股价在盘前交易中飙升8%，因为该公司表示，针对奥密克戎的新covid-19疫苗可能会在2022年初准备就绪。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/660e8ece7a2b338498e4bfe9f3c38228\" tg-width=\"851\" tg-height=\"616\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Moderna&nbsp;chief medical officer Paul Burton said he suspects the new Omicron coronavirus variant may elude current vaccines, and if so, a reformulated shot could be available early in the new year.</p><p><blockquote>Moderna首席医疗官保罗·伯顿(Paul Burton)表示，他怀疑新的奥密克戎冠状病毒变种可能会躲避目前的疫苗，如果是这样，重新配制的疫苗可能会在新年伊始上市。</blockquote></p><p> \"We should know about the ability of the current vaccine to provide protection in the next couple of weeks,\" Mr Burton said on Sunday (Nov 28) on the BBC's Andrew Marr Show.</p><p><blockquote>伯顿周日（11月28日）在BBC的安德鲁·马尔节目中表示：“我们应该了解当前疫苗在未来几周内提供保护的能力。”</blockquote></p><p> \"If we have to make a brand new vaccine, I think that's going to be early 2022 before that's really going to be available in large quantities,\" he said.</p><p><blockquote>“如果我们必须制造一种全新的疫苗，我认为要到2022年初才能真正大量上市，”他说。</blockquote></p><p> \"The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast,\" he added.</p><p><blockquote>“mRNA疫苗Moderna平台的非凡之处在于我们可以非常快地行动，”他补充道。</blockquote></p><p> The Cambridge, Massachusetts-based biotech company mobilised \"hundreds\" of staff early last&nbsp;Thursday, Thanksgiving Day in the United States, after news of the Omicron variant spread.</p><p><blockquote>在奥密克戎变种病毒的消息传开后，这家总部位于麻省剑桥的生物技术公司于上周四美国感恩节早些时候动员了“数百名”员工。</blockquote></p><p> Protection should still exist, depending on how long ago a person was vaccinated, and for now the best advice is to take one of the current Covid-19 vaccines, Mr Burton said.</p><p><blockquote>伯顿先生说，保护应该仍然存在，这取决于一个人多久前接种疫苗，目前最好的建议是接种一种当前的新冠肺炎疫苗。</blockquote></p><p> \"If people are on the fence, and you haven't been vaccinated, get vaccinated,\" he said. \"This is a dangerous-looking virus, but I think we have many tools in our armamentarium now to fight it.\"</p><p><blockquote>“如果人们持观望态度，而你还没有接种疫苗，那就接种疫苗，”他说。“这是一种看起来很危险的病毒，但我认为我们现在的医疗设备中有很多工具来对抗它。”</blockquote></p><p> The emergence of the Omicron strain has seen countries rush to clamp down on travel from southern Africa.</p><p><blockquote>奥密克戎病毒株的出现导致各国急于限制来自南部非洲的旅行。</blockquote></p><p> Fears that it could exacerbate a winter Covid-19 surge in the northern hemisphere and undermine a global economic recovery sent a wave of risk aversion across global markets last&nbsp;Friday that continued on Sunday when the Middle East opened for the week.</p><p><blockquote>由于担心这可能会加剧北半球冬季Covid-19激增并破坏全球经济复苏，上周五全球市场掀起了一波避险浪潮，并在周日中东本周开盘时持续。</blockquote></p><p> Moderna said in a release on Friday that it was working rapidly to test the current vaccine against the Omicron variant, and studying two booster candidates.</p><p><blockquote>Moderna在周五的一份新闻稿中表示，它正在迅速测试目前针对奥密克戎变种的疫苗，并研究两种候选加强剂。</blockquote></p><p> \"Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern,\" the company said. \"The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60 to 90 days.\"</p><p><blockquote>该公司表示：“自2021年初以来，Moderna制定了一项全面的战略，以预测令人担忧的新变种。”“该公司已多次证明有能力在60至90天内将新候选药物推进临床测试。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106015985","content_text":"Moderna stock surged 8% in premarket trading as it said new covid-19 vaccine for Omicron might be ready in early 2022.\n\nModerna chief medical officer Paul Burton said he suspects the new Omicron coronavirus variant may elude current vaccines, and if so, a reformulated shot could be available early in the new year.\n\"We should know about the ability of the current vaccine to provide protection in the next couple of weeks,\" Mr Burton said on Sunday (Nov 28) on the BBC's Andrew Marr Show.\n\"If we have to make a brand new vaccine, I think that's going to be early 2022 before that's really going to be available in large quantities,\" he said.\n\"The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast,\" he added.\nThe Cambridge, Massachusetts-based biotech company mobilised \"hundreds\" of staff early last Thursday, Thanksgiving Day in the United States, after news of the Omicron variant spread.\nProtection should still exist, depending on how long ago a person was vaccinated, and for now the best advice is to take one of the current Covid-19 vaccines, Mr Burton said.\n\"If people are on the fence, and you haven't been vaccinated, get vaccinated,\" he said. \"This is a dangerous-looking virus, but I think we have many tools in our armamentarium now to fight it.\"\nThe emergence of the Omicron strain has seen countries rush to clamp down on travel from southern Africa.\nFears that it could exacerbate a winter Covid-19 surge in the northern hemisphere and undermine a global economic recovery sent a wave of risk aversion across global markets last Friday that continued on Sunday when the Middle East opened for the week.\nModerna said in a release on Friday that it was working rapidly to test the current vaccine against the Omicron variant, and studying two booster candidates.\n\"Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern,\" the company said. \"The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60 to 90 days.\"","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":884,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877248717,"gmtCreate":1637938674890,"gmtModify":1637938674890,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"To the moon!&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>[财迷]&nbsp;[财迷]&nbsp;","listText":"To the moon!&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>[财迷]&nbsp;[财迷]&nbsp;","text":"To the moon! $Moderna, Inc.(MRNA)$[财迷] [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877248717","repostId":"1125886564","repostType":2,"repost":{"id":"1125886564","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637938179,"share":"https://www.laohu8.com/m/news/1125886564?lang=zh_CN&edition=full","pubTime":"2021-11-26 22:49","market":"us","language":"en","title":"Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.<blockquote>疫苗股早盘持续走高，Moderna股价大涨超23%。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125886564","media":"Tiger Newspress","summary":"Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23% and BioNTech ","content":"<p>Vaccine&nbsp;stocks&nbsp;continued&nbsp;to&nbsp;rise&nbsp;in&nbsp;early&nbsp;trading,&nbsp;Moderna&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;23%&nbsp;and&nbsp;BioNTech&nbsp;jumped&nbsp;nearly&nbsp;19%.<img src=\"https://static.tigerbbs.com/2e9f40662925ec57d0176cf5f1e36df4\" tg-width=\"876\" tg-height=\"613\" referrerpolicy=\"no-referrer\">Germany's BioNTech &nbsp;said it is studying the effectiveness of its COVID-19 vaccine against the new B.1.1.529 variant detected in South Africa - The Economic Times.</p><p><blockquote>疫苗股早盘持续走高，Moderna股价大涨超23%，BioNTech大涨近19%。德国BioNTech表示，正在研究其新冠肺炎疫苗对在南非发现的新B.1.1.529变种的有效性-经济时报。</blockquote></p><p> \"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,\" a BioNTech spokesperson said.</p><p><blockquote>“我们预计最迟在两周内从实验室测试中获得更多数据。这些数据将提供更多信息，说明B.1.1.529是否可能是一种逃逸变体，如果该变体在全球传播，可能需要调整我们的疫苗，”BioNTech发言人表示。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.<blockquote>疫苗股早盘持续走高，Moderna股价大涨超23%。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.<blockquote>疫苗股早盘持续走高，Moderna股价大涨超23%。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-26 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Vaccine&nbsp;stocks&nbsp;continued&nbsp;to&nbsp;rise&nbsp;in&nbsp;early&nbsp;trading,&nbsp;Moderna&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;23%&nbsp;and&nbsp;BioNTech&nbsp;jumped&nbsp;nearly&nbsp;19%.<img src=\"https://static.tigerbbs.com/2e9f40662925ec57d0176cf5f1e36df4\" tg-width=\"876\" tg-height=\"613\" referrerpolicy=\"no-referrer\">Germany's BioNTech &nbsp;said it is studying the effectiveness of its COVID-19 vaccine against the new B.1.1.529 variant detected in South Africa - The Economic Times.</p><p><blockquote>疫苗股早盘持续走高，Moderna股价大涨超23%，BioNTech大涨近19%。德国BioNTech表示，正在研究其新冠肺炎疫苗对在南非发现的新B.1.1.529变种的有效性-经济时报。</blockquote></p><p> \"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,\" a BioNTech spokesperson said.</p><p><blockquote>“我们预计最迟在两周内从实验室测试中获得更多数据。这些数据将提供更多信息，说明B.1.1.529是否可能是一种逃逸变体，如果该变体在全球传播，可能需要调整我们的疫苗，”BioNTech发言人表示。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125886564","content_text":"Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23% and BioNTech jumped nearly 19%.Germany's BioNTech  said it is studying the effectiveness of its COVID-19 vaccine against the new B.1.1.529 variant detected in South Africa - The Economic Times.\n\"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,\" a BioNTech spokesperson said.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1066,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":874886130,"gmtCreate":1637757497676,"gmtModify":1637760515797,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"Buy the dip and let's wait for the climb.&nbsp;[财迷]&nbsp;<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>https://www.businesstimes.com.sg/companies-markets/brokers-take-dbs-raises-sea-tp-to-us402-on-higher-valuation-from-e-commerce","listText":"Buy the dip and let's wait for the climb.&nbsp;[财迷]&nbsp;<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>https://www.businesstimes.com.sg/companies-markets/brokers-take-dbs-raises-sea-tp-to-us402-on-higher-valuation-from-e-commerce","text":"Buy the dip and let's wait for the climb. [财迷] $Sea Ltd(SE)$https://www.businesstimes.com.sg/companies-markets/brokers-take-dbs-raises-sea-tp-to-us402-on-higher-valuation-from-e-commerce","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/874886130","isVote":1,"tweetType":1,"viewCount":1177,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872838004,"gmtCreate":1637469763226,"gmtModify":1637469763226,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"more to grow&nbsp;[财迷]&nbsp;","listText":"more to grow&nbsp;[财迷]&nbsp;","text":"more to grow [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872838004","repostId":"1129693973","repostType":4,"repost":{"id":"1129693973","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637332940,"share":"https://www.laohu8.com/m/news/1129693973?lang=zh_CN&edition=full","pubTime":"2021-11-19 22:42","market":"us","language":"en","title":"Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading<blockquote>Moderna早盘上涨超过8%，辉瑞和BioNTech SE上涨约2%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1129693973","media":"Tiger Newspress","summary":"Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading.Pfizer(PFE.US)","content":"<p>Moderna jumped over&nbsp;8% while Pfizer and BioNTech SE rose around 2% in morning trading.<img src=\"https://static.tigerbbs.com/1788750b32795d8eb3fbb1f2b7eb08a3\" tg-width=\"773\" tg-height=\"565\" referrerpolicy=\"no-referrer\">Pfizer(PFE.US) plans to apply to the European Union for authorization of its COVID-19 drug Paxlovid today.In addition, the report pointed out that German Health Minister Jens Spahn planned to purchase Paxlovid.</p><p><blockquote>Moderna在早盘交易中上涨超过8%，而辉瑞和BioNTech SE上涨约2%。辉瑞（PFE.US）计划今日向欧盟申请其新冠药物Paxlovid的授权。此外，报道指出，德国卫生部长延斯·施潘计划采购Paxlovid。</blockquote></p><p> The report quoted a spokesman for the German Ministry of Health as saying: \"The Ministry of Health is in contact with Pfizer on the possible purchase of COVID-19 drug Paxlovid.\"</p><p><blockquote>报道援引德国卫生部发言人的话说：“卫生部正在与辉瑞就可能购买新冠药物Paxlovid进行接触。”</blockquote></p><p> Moreover，Moderna, Inc.&nbsp;today announced that the&nbsp;U.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p><p><blockquote>此外，Moderna公司今天宣布，美国。美国食品药品监督管理局(FDA)已将50µg剂量水平的Moderna COVID-19疫苗加强剂量的紧急使用授权扩大到所有18岁及以上的成年人。这种加强剂可用于所有18岁及以上已完成任何其他授权或批准的新冠肺炎疫苗初次接种的个人。</blockquote></p><p> “This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p><p><blockquote>Moderna首席执行官Stéphane Bancel表示：“这项紧急使用授权是在我们进入冬季并面临全国范围内不断增加的COVID-19病例数和住院人数的关键时刻发布的。”“我们感谢FDA的审查，并对强有力的临床证据充满信心，即50µg加强剂量的mRNA-1273可诱导针对COVID-19的强烈免疫反应。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading<blockquote>Moderna早盘上涨超过8%，辉瑞和BioNTech SE上涨约2%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading<blockquote>Moderna早盘上涨超过8%，辉瑞和BioNTech SE上涨约2%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-19 22:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna jumped over&nbsp;8% while Pfizer and BioNTech SE rose around 2% in morning trading.<img src=\"https://static.tigerbbs.com/1788750b32795d8eb3fbb1f2b7eb08a3\" tg-width=\"773\" tg-height=\"565\" referrerpolicy=\"no-referrer\">Pfizer(PFE.US) plans to apply to the European Union for authorization of its COVID-19 drug Paxlovid today.In addition, the report pointed out that German Health Minister Jens Spahn planned to purchase Paxlovid.</p><p><blockquote>Moderna在早盘交易中上涨超过8%，而辉瑞和BioNTech SE上涨约2%。辉瑞（PFE.US）计划今日向欧盟申请其新冠药物Paxlovid的授权。此外，报道指出，德国卫生部长延斯·施潘计划采购Paxlovid。</blockquote></p><p> The report quoted a spokesman for the German Ministry of Health as saying: \"The Ministry of Health is in contact with Pfizer on the possible purchase of COVID-19 drug Paxlovid.\"</p><p><blockquote>报道援引德国卫生部发言人的话说：“卫生部正在与辉瑞就可能购买新冠药物Paxlovid进行接触。”</blockquote></p><p> Moreover，Moderna, Inc.&nbsp;today announced that the&nbsp;U.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p><p><blockquote>此外，Moderna公司今天宣布，美国。美国食品药品监督管理局(FDA)已将50µg剂量水平的Moderna COVID-19疫苗加强剂量的紧急使用授权扩大到所有18岁及以上的成年人。这种加强剂可用于所有18岁及以上已完成任何其他授权或批准的新冠肺炎疫苗初次接种的个人。</blockquote></p><p> “This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p><p><blockquote>Moderna首席执行官Stéphane Bancel表示：“这项紧急使用授权是在我们进入冬季并面临全国范围内不断增加的COVID-19病例数和住院人数的关键时刻发布的。”“我们感谢FDA的审查，并对强有力的临床证据充满信心，即50µg加强剂量的mRNA-1273可诱导针对COVID-19的强烈免疫反应。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129693973","content_text":"Moderna jumped over 8% while Pfizer and BioNTech SE rose around 2% in morning trading.Pfizer(PFE.US) plans to apply to the European Union for authorization of its COVID-19 drug Paxlovid today.In addition, the report pointed out that German Health Minister Jens Spahn planned to purchase Paxlovid.\nThe report quoted a spokesman for the German Ministry of Health as saying: \"The Ministry of Health is in contact with Pfizer on the possible purchase of COVID-19 drug Paxlovid.\"\nMoreover，Moderna, Inc. today announced that the U.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”","news_type":1,"symbols_score_info":{"MRNA":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1260,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":876591196,"gmtCreate":1637329144369,"gmtModify":1637329144469,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"about time! so many different studies have showed increased protection with&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>","listText":"about time! so many different studies have showed increased protection with&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>","text":"about time! so many different studies have showed increased protection with $Moderna, Inc.(MRNA)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876591196","repostId":"1138047553","repostType":2,"repost":{"id":"1138047553","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637327403,"share":"https://www.laohu8.com/m/news/1138047553?lang=zh_CN&edition=full","pubTime":"2021-11-19 21:10","market":"us","language":"en","title":"Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older<blockquote>Moderna宣布FDA授权美国18岁及以上成年人接种新冠疫苗加强剂量</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1138047553","media":"Tiger Newspress","summary":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of C","content":"<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p><p><blockquote>在宣布FDA授权美国18岁及以上成年人接种加强剂量的COVID-19疫苗后，Moderna股价在盘前交易中飙升4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p><p><blockquote>Moderna公司今天宣布，美国。美国食品药品监督管理局(FDA)已将50µg剂量水平的Moderna COVID-19疫苗加强剂量的紧急使用授权扩大到所有18岁及以上的成年人。这种加强剂可用于所有18岁及以上已完成任何其他授权或批准的新冠肺炎疫苗初次接种的个人。</blockquote></p><p> “This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p><p><blockquote>Moderna首席执行官Stéphane Bancel表示：“这项紧急使用授权是在我们进入冬季并面临全国范围内不断增加的COVID-19病例数和住院人数的关键时刻发布的。”“我们感谢FDA的审查，并对强有力的临床证据充满信心，即50µg加强剂量的mRNA-1273可诱导针对COVID-19的强烈免疫反应。”</blockquote></p><p> The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p><p><blockquote>加强剂量将在完成任何初级系列新冠肺炎疫苗接种后至少六个月进行。10月20日，FDA授权65岁及以上人群以及18至64岁严重COVID-19高风险成年人紧急使用50µg剂量水平的Moderna COVID-19疫苗加强剂量；以及经常在机构或职业上接触新型冠状病毒的18至64岁人群。在许多国际市场上，Moderna新冠肺炎加强疫苗被授权用于18岁及以上的成年人，无论职业风险因素如何。此前，100µg mRNA 1273第三剂在免疫功能低下个体中获得批准。</blockquote></p><p> The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p><p><blockquote>FDA根据该公司分享的全部科学证据制定了该EUA，包括mRNA-1273 2期临床研究的数据分析，该研究经过修订，以提供50µg剂量水平的mRNA-1273加强剂量。第二次给药后6-8个月感兴趣的参与者(n=344)。中和抗体滴度在加强之前减弱，特别是针对关注的变体，在大约6个月时。值得注意的是，50µg剂量水平的mRNA-1273加强剂量将中和滴度提高到显著高于3期基准。加强剂量后的安全性概况与先前针对mRNA-1273剂量2观察到的相似。</blockquote></p><p> As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p><p><blockquote>下一步，美国。美国疾病控制和预防中心（CDC）免疫实践咨询委员会（ACIP）将开会讨论向美国人推出新冠肺炎加强剂的潜在建议。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older<blockquote>Moderna宣布FDA授权美国18岁及以上成年人接种新冠疫苗加强剂量</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older<blockquote>Moderna宣布FDA授权美国18岁及以上成年人接种新冠疫苗加强剂量</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-19 21:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p><p><blockquote>在宣布FDA授权美国18岁及以上成年人接种加强剂量的COVID-19疫苗后，Moderna股价在盘前交易中飙升4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p><p><blockquote>Moderna公司今天宣布，美国。美国食品药品监督管理局(FDA)已将50µg剂量水平的Moderna COVID-19疫苗加强剂量的紧急使用授权扩大到所有18岁及以上的成年人。这种加强剂可用于所有18岁及以上已完成任何其他授权或批准的新冠肺炎疫苗初次接种的个人。</blockquote></p><p> “This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p><p><blockquote>Moderna首席执行官Stéphane Bancel表示：“这项紧急使用授权是在我们进入冬季并面临全国范围内不断增加的COVID-19病例数和住院人数的关键时刻发布的。”“我们感谢FDA的审查，并对强有力的临床证据充满信心，即50µg加强剂量的mRNA-1273可诱导针对COVID-19的强烈免疫反应。”</blockquote></p><p> The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p><p><blockquote>加强剂量将在完成任何初级系列新冠肺炎疫苗接种后至少六个月进行。10月20日，FDA授权65岁及以上人群以及18至64岁严重COVID-19高风险成年人紧急使用50µg剂量水平的Moderna COVID-19疫苗加强剂量；以及经常在机构或职业上接触新型冠状病毒的18至64岁人群。在许多国际市场上，Moderna新冠肺炎加强疫苗被授权用于18岁及以上的成年人，无论职业风险因素如何。此前，100µg mRNA 1273第三剂在免疫功能低下个体中获得批准。</blockquote></p><p> The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p><p><blockquote>FDA根据该公司分享的全部科学证据制定了该EUA，包括mRNA-1273 2期临床研究的数据分析，该研究经过修订，以提供50µg剂量水平的mRNA-1273加强剂量。第二次给药后6-8个月感兴趣的参与者(n=344)。中和抗体滴度在加强之前减弱，特别是针对关注的变体，在大约6个月时。值得注意的是，50µg剂量水平的mRNA-1273加强剂量将中和滴度提高到显著高于3期基准。加强剂量后的安全性概况与先前针对mRNA-1273剂量2观察到的相似。</blockquote></p><p> As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p><p><blockquote>下一步，美国。美国疾病控制和预防中心（CDC）免疫实践咨询委员会（ACIP）将开会讨论向美国人推出新冠肺炎加强剂的潜在建议。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138047553","content_text":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.\n\nModerna, Inc. today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”\nThe booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.\nThe FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.\nAs a next step, theU.S. Centers for Disease Controland Prevention’s (CDC) Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1041,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":833712317,"gmtCreate":1629262600439,"gmtModify":1631884077863,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"Honestly in my humble opinion, with the strong and rapid spread of the delta variant, there's going to be an increase in demand for vaccine jabs and booster jabs - making&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>a very much keep-worthy stock vs. dumping it.&nbsp;","listText":"Honestly in my humble opinion, with the strong and rapid spread of the delta variant, there's going to be an increase in demand for vaccine jabs and booster jabs - making&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>a very much keep-worthy stock vs. dumping it.&nbsp;","text":"Honestly in my humble opinion, with the strong and rapid spread of the delta variant, there's going to be an increase in demand for vaccine jabs and booster jabs - making $Moderna, Inc.(MRNA)$a very much keep-worthy stock vs. dumping it.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/833712317","isVote":1,"tweetType":1,"viewCount":758,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000221","authorId":"9000000000000221","name":"搞钱树","avatar":"https://static.tigerbbs.com/82edc4968feb7c0c481f5ad38d9a498b","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000221","authorIdStr":"9000000000000221"},"content":"一直比较关注$莫德纳公司(MRNA)$ ，只不过以前太痴情中概股，现在改变了，只不过还能买吗？","text":"一直比较关注$莫德纳公司(MRNA)$ ，只不过以前太痴情中概股，现在改变了，只不过还能买吗？","html":"一直比较关注$莫德纳公司(MRNA)$ ，只不过以前太痴情中概股，现在改变了，只不过还能买吗？"},{"author":{"id":"9000000000000159","authorId":"9000000000000159","name":"宝宝金水_","avatar":"https://static.tigerbbs.com/3277b62086966882a8b4e45d9f8b88bb","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000159","authorIdStr":"9000000000000159"},"content":"看样子昨天确实是买点呀，今天看看要是有合适的价格也买一丢丢。","text":"看样子昨天确实是买点呀，今天看看要是有合适的价格也买一丢丢。","html":"看样子昨天确实是买点呀，今天看看要是有合适的价格也买一丢丢。"}],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":833712317,"gmtCreate":1629262600439,"gmtModify":1631884077863,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"Honestly in my humble opinion, with the strong and rapid spread of the delta variant, there's going to be an increase in demand for vaccine jabs and booster jabs - making&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>a very much keep-worthy stock vs. dumping it.&nbsp;","listText":"Honestly in my humble opinion, with the strong and rapid spread of the delta variant, there's going to be an increase in demand for vaccine jabs and booster jabs - making&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>a very much keep-worthy stock vs. dumping it.&nbsp;","text":"Honestly in my humble opinion, with the strong and rapid spread of the delta variant, there's going to be an increase in demand for vaccine jabs and booster jabs - making $Moderna, Inc.(MRNA)$a very much keep-worthy stock vs. dumping it.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/833712317","isVote":1,"tweetType":1,"viewCount":758,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000221","authorId":"9000000000000221","name":"搞钱树","avatar":"https://static.tigerbbs.com/82edc4968feb7c0c481f5ad38d9a498b","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000221","authorIdStr":"9000000000000221"},"content":"一直比较关注$莫德纳公司(MRNA)$ ，只不过以前太痴情中概股，现在改变了，只不过还能买吗？","text":"一直比较关注$莫德纳公司(MRNA)$ ，只不过以前太痴情中概股，现在改变了，只不过还能买吗？","html":"一直比较关注$莫德纳公司(MRNA)$ ，只不过以前太痴情中概股，现在改变了，只不过还能买吗？"},{"author":{"id":"9000000000000159","authorId":"9000000000000159","name":"宝宝金水_","avatar":"https://static.tigerbbs.com/3277b62086966882a8b4e45d9f8b88bb","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000159","authorIdStr":"9000000000000159"},"content":"看样子昨天确实是买点呀，今天看看要是有合适的价格也买一丢丢。","text":"看样子昨天确实是买点呀，今天看看要是有合适的价格也买一丢丢。","html":"看样子昨天确实是买点呀，今天看看要是有合适的价格也买一丢丢。"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":876591196,"gmtCreate":1637329144369,"gmtModify":1637329144469,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"about time! so many different studies have showed increased protection with&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>","listText":"about time! so many different studies have showed increased protection with&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>","text":"about time! so many different studies have showed increased protection with $Moderna, Inc.(MRNA)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/876591196","repostId":"1138047553","repostType":2,"repost":{"id":"1138047553","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637327403,"share":"https://www.laohu8.com/m/news/1138047553?lang=zh_CN&edition=full","pubTime":"2021-11-19 21:10","market":"us","language":"en","title":"Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older<blockquote>Moderna宣布FDA授权美国18岁及以上成年人接种新冠疫苗加强剂量</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1138047553","media":"Tiger Newspress","summary":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of C","content":"<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p><p><blockquote>在宣布FDA授权美国18岁及以上成年人接种加强剂量的COVID-19疫苗后，Moderna股价在盘前交易中飙升4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p><p><blockquote>Moderna公司今天宣布，美国。美国食品药品监督管理局(FDA)已将50µg剂量水平的Moderna COVID-19疫苗加强剂量的紧急使用授权扩大到所有18岁及以上的成年人。这种加强剂可用于所有18岁及以上已完成任何其他授权或批准的新冠肺炎疫苗初次接种的个人。</blockquote></p><p> “This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p><p><blockquote>Moderna首席执行官Stéphane Bancel表示：“这项紧急使用授权是在我们进入冬季并面临全国范围内不断增加的COVID-19病例数和住院人数的关键时刻发布的。”“我们感谢FDA的审查，并对强有力的临床证据充满信心，即50µg加强剂量的mRNA-1273可诱导针对COVID-19的强烈免疫反应。”</blockquote></p><p> The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p><p><blockquote>加强剂量将在完成任何初级系列新冠肺炎疫苗接种后至少六个月进行。10月20日，FDA授权65岁及以上人群以及18至64岁严重COVID-19高风险成年人紧急使用50µg剂量水平的Moderna COVID-19疫苗加强剂量；以及经常在机构或职业上接触新型冠状病毒的18至64岁人群。在许多国际市场上，Moderna新冠肺炎加强疫苗被授权用于18岁及以上的成年人，无论职业风险因素如何。此前，100µg mRNA 1273第三剂在免疫功能低下个体中获得批准。</blockquote></p><p> The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p><p><blockquote>FDA根据该公司分享的全部科学证据制定了该EUA，包括mRNA-1273 2期临床研究的数据分析，该研究经过修订，以提供50µg剂量水平的mRNA-1273加强剂量。第二次给药后6-8个月感兴趣的参与者(n=344)。中和抗体滴度在加强之前减弱，特别是针对关注的变体，在大约6个月时。值得注意的是，50µg剂量水平的mRNA-1273加强剂量将中和滴度提高到显著高于3期基准。加强剂量后的安全性概况与先前针对mRNA-1273剂量2观察到的相似。</blockquote></p><p> As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p><p><blockquote>下一步，美国。美国疾病控制和预防中心（CDC）免疫实践咨询委员会（ACIP）将开会讨论向美国人推出新冠肺炎加强剂的潜在建议。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older<blockquote>Moderna宣布FDA授权美国18岁及以上成年人接种新冠疫苗加强剂量</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older<blockquote>Moderna宣布FDA授权美国18岁及以上成年人接种新冠疫苗加强剂量</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-19 21:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock surged 4% in premarket trading&nbsp;after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.</p><p><blockquote>在宣布FDA授权美国18岁及以上成年人接种加强剂量的COVID-19疫苗后，Moderna股价在盘前交易中飙升4%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/b8db683899273d344e819a53f4b3366b\" tg-width=\"850\" tg-height=\"620\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Moderna, Inc.&nbsp;today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.</p><p><blockquote>Moderna公司今天宣布，美国。美国食品药品监督管理局(FDA)已将50µg剂量水平的Moderna COVID-19疫苗加强剂量的紧急使用授权扩大到所有18岁及以上的成年人。这种加强剂可用于所有18岁及以上已完成任何其他授权或批准的新冠肺炎疫苗初次接种的个人。</blockquote></p><p> “This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”</p><p><blockquote>Moderna首席执行官Stéphane Bancel表示：“这项紧急使用授权是在我们进入冬季并面临全国范围内不断增加的COVID-19病例数和住院人数的关键时刻发布的。”“我们感谢FDA的审查，并对强有力的临床证据充满信心，即50µg加强剂量的mRNA-1273可诱导针对COVID-19的强烈免疫反应。”</blockquote></p><p> The booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.</p><p><blockquote>加强剂量将在完成任何初级系列新冠肺炎疫苗接种后至少六个月进行。10月20日，FDA授权65岁及以上人群以及18至64岁严重COVID-19高风险成年人紧急使用50µg剂量水平的Moderna COVID-19疫苗加强剂量；以及经常在机构或职业上接触新型冠状病毒的18至64岁人群。在许多国际市场上，Moderna新冠肺炎加强疫苗被授权用于18岁及以上的成年人，无论职业风险因素如何。此前，100µg mRNA 1273第三剂在免疫功能低下个体中获得批准。</blockquote></p><p> The FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.</p><p><blockquote>FDA根据该公司分享的全部科学证据制定了该EUA，包括mRNA-1273 2期临床研究的数据分析，该研究经过修订，以提供50µg剂量水平的mRNA-1273加强剂量。第二次给药后6-8个月感兴趣的参与者(n=344)。中和抗体滴度在加强之前减弱，特别是针对关注的变体，在大约6个月时。值得注意的是，50µg剂量水平的mRNA-1273加强剂量将中和滴度提高到显著高于3期基准。加强剂量后的安全性概况与先前针对mRNA-1273剂量2观察到的相似。</blockquote></p><p> As a next step, theU.S. Centers for Disease Controland Prevention’s (CDC)&nbsp;Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.</p><p><blockquote>下一步，美国。美国疾病控制和预防中心（CDC）免疫实践咨询委员会（ACIP）将开会讨论向美国人推出新冠肺炎加强剂的潜在建议。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138047553","content_text":"Moderna stock surged 4% in premarket trading after announcing FDA authorization of booster dose of COVID-19 Vaccine in the U.S. for adults 18 years and older.\n\nModerna, Inc. today announced that theU.S. Food and Drug Administration(FDA) has extended the emergency use authorization of a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level to all adults aged 18 and older. This booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.\n“This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country,” saidStéphane Bancel, Chief Executive Officer ofModerna. “We thank the FDA for their review, and are confident in the robust clinical evidence that a 50 µg booster dose of mRNA-1273 induces a strong immune response against COVID-19.”\nThe booster dose is to be administered at least six months after completion of any primary series COVID-19 vaccination. OnOctober 20th, the FDAauthorizedfor emergency use a booster dose of the Moderna COVID-19 vaccine at the 50 µg dose level for people aged 65 and older as well as adults aged 18 to 64 who are at high risk of severe COVID-19; and people aged 18 to 64 with frequent institutional or occupational exposure to SARS-CoV-2. The Moderna COVID-19 booster vaccine is authorized for adults ages 18 and above regardless of occupational risk factors in many international markets. This follows the earlier approval of the 100 µg mRNA 1273 third dose in immunocompromised individuals.\nThe FDA based this EUA on the totality of scientific evidence shared by the company including a data analysis from the Phase 2 clinical study of mRNA-1273, which was amended to offer a booster dose of mRNA-1273 at the 50 µg dose level to interested participants 6-8 months following their second dose (n=344). Neutralizing antibody titers had waned prior to boosting, particularly against variants of concern, at approximately 6 months. Notably, a booster dose of mRNA-1273 at the 50 µg dose level boosted neutralizing titers significantly above the Phase 3 benchmark. The safety profile following the booster dose was similar to that observed previously for dose 2 of mRNA-1273.\nAs a next step, theU.S. Centers for Disease Controland Prevention’s (CDC) Advisory Committee on Immunization Practices(ACIP) will meet to discuss a potential recommendation for rollout of COVID-19 boosters to Americans.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1041,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602132570,"gmtCreate":1638979550717,"gmtModify":1638979550717,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"to the moon!&nbsp;[Cool]&nbsp;[Cool]&nbsp;","listText":"to the moon!&nbsp;[Cool]&nbsp;[Cool]&nbsp;","text":"to the moon! [Cool] [Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602132570","repostId":"1161444269","repostType":4,"repost":{"id":"1161444269","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638977215,"share":"https://www.laohu8.com/m/news/1161444269?lang=zh_CN&edition=full","pubTime":"2021-12-08 23:26","market":"us","language":"en","title":"Apple shares rose nearly 2% to a new high<blockquote>苹果股价上涨近2%，创新高</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1161444269","media":"Tiger Newspress","summary":"Apple shares rose nearly 2% to a new high in morning trading.","content":"<p>Apple shares rose nearly 2% to a new high&nbsp;in morning trading.</p><p><blockquote>苹果股价在早盘交易中上涨近2%，创下新高。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/9a9f5fdc1cb0a898675c515a39de7611\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apple shares rose nearly 2% to a new high<blockquote>苹果股价上涨近2%，创新高</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApple shares rose nearly 2% to a new high<blockquote>苹果股价上涨近2%，创新高</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-08 23:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Apple shares rose nearly 2% to a new high&nbsp;in morning trading.</p><p><blockquote>苹果股价在早盘交易中上涨近2%，创下新高。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/9a9f5fdc1cb0a898675c515a39de7611\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161444269","content_text":"Apple shares rose nearly 2% to a new high in morning trading.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":3489,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603132509,"gmtCreate":1638372243529,"gmtModify":1638372243668,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"A good time to buy in&nbsp;<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>[Cool]&nbsp;","listText":"A good time to buy in&nbsp;<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>[Cool]&nbsp;","text":"A good time to buy in $Sea Ltd(SE)$[Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603132509","repostId":"2186310769","repostType":2,"isVote":1,"tweetType":1,"viewCount":3260,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877248717,"gmtCreate":1637938674890,"gmtModify":1637938674890,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"To the moon!&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>[财迷]&nbsp;[财迷]&nbsp;","listText":"To the moon!&nbsp;<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>[财迷]&nbsp;[财迷]&nbsp;","text":"To the moon! $Moderna, Inc.(MRNA)$[财迷] [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877248717","repostId":"1125886564","repostType":2,"repost":{"id":"1125886564","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637938179,"share":"https://www.laohu8.com/m/news/1125886564?lang=zh_CN&edition=full","pubTime":"2021-11-26 22:49","market":"us","language":"en","title":"Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.<blockquote>疫苗股早盘持续走高，Moderna股价大涨超23%。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125886564","media":"Tiger Newspress","summary":"Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23% and BioNTech ","content":"<p>Vaccine&nbsp;stocks&nbsp;continued&nbsp;to&nbsp;rise&nbsp;in&nbsp;early&nbsp;trading,&nbsp;Moderna&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;23%&nbsp;and&nbsp;BioNTech&nbsp;jumped&nbsp;nearly&nbsp;19%.<img src=\"https://static.tigerbbs.com/2e9f40662925ec57d0176cf5f1e36df4\" tg-width=\"876\" tg-height=\"613\" referrerpolicy=\"no-referrer\">Germany's BioNTech &nbsp;said it is studying the effectiveness of its COVID-19 vaccine against the new B.1.1.529 variant detected in South Africa - The Economic Times.</p><p><blockquote>疫苗股早盘持续走高，Moderna股价大涨超23%，BioNTech大涨近19%。德国BioNTech表示，正在研究其新冠肺炎疫苗对在南非发现的新B.1.1.529变种的有效性-经济时报。</blockquote></p><p> \"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,\" a BioNTech spokesperson said.</p><p><blockquote>“我们预计最迟在两周内从实验室测试中获得更多数据。这些数据将提供更多信息，说明B.1.1.529是否可能是一种逃逸变体，如果该变体在全球传播，可能需要调整我们的疫苗，”BioNTech发言人表示。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.<blockquote>疫苗股早盘持续走高，Moderna股价大涨超23%。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks continued to rise in early trading, Moderna shares surged more than 23%.<blockquote>疫苗股早盘持续走高，Moderna股价大涨超23%。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-26 22:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Vaccine&nbsp;stocks&nbsp;continued&nbsp;to&nbsp;rise&nbsp;in&nbsp;early&nbsp;trading,&nbsp;Moderna&nbsp;shares&nbsp;surged&nbsp;more&nbsp;than&nbsp;23%&nbsp;and&nbsp;BioNTech&nbsp;jumped&nbsp;nearly&nbsp;19%.<img src=\"https://static.tigerbbs.com/2e9f40662925ec57d0176cf5f1e36df4\" tg-width=\"876\" tg-height=\"613\" referrerpolicy=\"no-referrer\">Germany's BioNTech &nbsp;said it is studying the effectiveness of its COVID-19 vaccine against the new B.1.1.529 variant detected in South Africa - The Economic Times.</p><p><blockquote>疫苗股早盘持续走高，Moderna股价大涨超23%，BioNTech大涨近19%。德国BioNTech表示，正在研究其新冠肺炎疫苗对在南非发现的新B.1.1.529变种的有效性-经济时报。</blockquote></p><p> \"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,\" a BioNTech spokesperson said.</p><p><blockquote>“我们预计最迟在两周内从实验室测试中获得更多数据。这些数据将提供更多信息，说明B.1.1.529是否可能是一种逃逸变体，如果该变体在全球传播，可能需要调整我们的疫苗，”BioNTech发言人表示。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125886564","content_text":"Vaccine stocks continued to rise in early trading, Moderna shares surged more than 23% and BioNTech jumped nearly 19%.Germany's BioNTech  said it is studying the effectiveness of its COVID-19 vaccine against the new B.1.1.529 variant detected in South Africa - The Economic Times.\n\"We expect more data from the laboratory tests in two weeks at the latest. These data will provide more information about whether B.1.1.529 could be an escape variant that may require an adjustment of our vaccine if the variant spreads globally,\" a BioNTech spokesperson said.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1066,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602453657,"gmtCreate":1639060563339,"gmtModify":1639061378393,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"very insightful article and shed some light on why&nbsp;<a href=\"https://laohu8.com/S/GRAB\">$Grab Holdings(GRAB)$</a>is doing so badly. only wish it came out earlier&nbsp;[Cry]&nbsp;","listText":"very insightful article and shed some light on why&nbsp;<a href=\"https://laohu8.com/S/GRAB\">$Grab Holdings(GRAB)$</a>is doing so badly. only wish it came out earlier&nbsp;[Cry]&nbsp;","text":"very insightful article and shed some light on why $Grab Holdings(GRAB)$is doing so badly. only wish it came out earlier [Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602453657","repostId":"2190614747","repostType":2,"isVote":1,"tweetType":1,"viewCount":4599,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602468206,"gmtCreate":1639058758922,"gmtModify":1639059675097,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"wanted to buy the dip but there isn't really a dip with&nbsp;[LOL]&nbsp;","listText":"wanted to buy the dip but there isn't really a dip with&nbsp;[LOL]&nbsp;","text":"wanted to buy the dip but there isn't really a dip with [LOL]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602468206","repostId":"1129645066","repostType":4,"repost":{"id":"1129645066","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639053071,"share":"https://www.laohu8.com/m/news/1129645066?lang=zh_CN&edition=full","pubTime":"2021-12-09 20:31","market":"us","language":"en","title":"Amazon shares fell slightly by 0.5% in premarket trading<blockquote>亚马逊股价在盘前交易中小幅下跌0.5%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1129645066","media":"Tiger Newspress","summary":"Amazon shares fell slightly by 0.5% in premarket trading after Italy's antitrust fined Amazon 1.13 b","content":"<p>Amazon shares fell slightly by 0.5% in premarket trading&nbsp;after&nbsp;Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.</p><p><blockquote>意大利反垄断机构因亚马逊涉嫌滥用市场支配地位对其处以11.3亿欧元罚款，亚马逊股价在盘前交易中小幅下跌0.5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1aa0616746882964f5e05a784287edeb\" tg-width=\"850\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Italy's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.</p><p><blockquote>意大利反垄断机构周四表示，已对电商巨头亚马逊处以11.3亿欧元（12.8亿美元）的罚款，原因是其涉嫌滥用市场支配地位。</blockquote></p><p> In a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.</p><p><blockquote>该监管机构在一份声明中表示，亚马逊损害了电子商务物流服务领域的竞争运营商。</blockquote></p><p> \"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.</p><p><blockquote>“亚马逊在意大利市场中介服务市场上占据主导地位，亚马逊利用这一优势鼓励活跃在Amazon.it上的卖家采用自己的物流服务——亚马逊物流(FBA)，从而损害了竞争运营商提供的物流服务，并加强其自身的主导地位，”它补充道。</blockquote></p><p> The antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.</p><p><blockquote>反垄断机构表示，将对亚马逊采取纠正措施，这些措施将接受监督受托人的审查。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon shares fell slightly by 0.5% in premarket trading<blockquote>亚马逊股价在盘前交易中小幅下跌0.5%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon shares fell slightly by 0.5% in premarket trading<blockquote>亚马逊股价在盘前交易中小幅下跌0.5%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-09 20:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Amazon shares fell slightly by 0.5% in premarket trading&nbsp;after&nbsp;Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.</p><p><blockquote>意大利反垄断机构因亚马逊涉嫌滥用市场支配地位对其处以11.3亿欧元罚款，亚马逊股价在盘前交易中小幅下跌0.5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1aa0616746882964f5e05a784287edeb\" tg-width=\"850\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> Italy's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.</p><p><blockquote>意大利反垄断机构周四表示，已对电商巨头亚马逊处以11.3亿欧元（12.8亿美元）的罚款，原因是其涉嫌滥用市场支配地位。</blockquote></p><p> In a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.</p><p><blockquote>该监管机构在一份声明中表示，亚马逊损害了电子商务物流服务领域的竞争运营商。</blockquote></p><p> \"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.</p><p><blockquote>“亚马逊在意大利市场中介服务市场上占据主导地位，亚马逊利用这一优势鼓励活跃在Amazon.it上的卖家采用自己的物流服务——亚马逊物流(FBA)，从而损害了竞争运营商提供的物流服务，并加强其自身的主导地位，”它补充道。</blockquote></p><p> The antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.</p><p><blockquote>反垄断机构表示，将对亚马逊采取纠正措施，这些措施将接受监督受托人的审查。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129645066","content_text":"Amazon shares fell slightly by 0.5% in premarket trading after Italy's antitrust fined Amazon 1.13 bln euros for alleged abuse of market dominance.\n\nItaly's antitrust said on Thursday it had fined e-commerce giant Amazon 1.13 billion euros ($1.28 billion) for alleged abuse of market dominance.\nIn a statement the watchdog said Amazon had harmed competing operators in the e-commerce logistics service.\n\"Amazon holds a dominant position in the Italian market for intermediation services on marketplaces, which Amazon leveraged to favour the adoption of its own logistics service - Fulfilment by Amazon (FBA) - by sellers active on Amazon.it to the detriment of the logistics services offered by competing operators, as well as to strengthen its own dominant position,\" it added.\nThe antitrust said it would impose on Amazon corrective steps that will be subject to review by a monitoring trustee.","news_type":1,"symbols_score_info":{"AMZN":0.9}},"isVote":1,"tweetType":1,"viewCount":2996,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699232578,"gmtCreate":1639805865423,"gmtModify":1639805865534,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"mmmm&nbsp;","listText":"mmmm&nbsp;","text":"mmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699232578","repostId":"1109831591","repostType":4,"repost":{"id":"1109831591","kind":"news","pubTimestamp":1639804463,"share":"https://www.laohu8.com/m/news/1109831591?lang=zh_CN&edition=full","pubTime":"2021-12-18 13:14","market":"us","language":"en","title":"Why Pfizer and Johnson & Johnson Fell on Friday<blockquote>辉瑞和强生周五为何下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1109831591","media":"Motley Fool","summary":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnso","content":"<p>What happened</p><p><blockquote>发生了什么</blockquote></p><p> Two prominent U.S. coronavirus stocks ended the week on a down note.&nbsp;<a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>&nbsp;and&nbsp;<a href=\"https://laohu8.com/S/JNJ\"><b>Johnson &amp; Johnson</b></a>&nbsp;both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.</p><p><blockquote>两只著名的美国冠状病毒股票本周收盘下跌。<a href=\"https://laohu8.com/S/PFE\"><b>辉瑞</b></a>和<a href=\"https://laohu8.com/S/JNJ\"><b>强生公司</b></a>当日均跌近3%。此前，一家著名投资银行对其当前前景持相当冷淡的看法。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c6a2f152eebbe10f5ab65a99815f461c\" tg-width=\"975\" tg-height=\"637\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> So what</p><p><blockquote>那又怎样</blockquote></p><p> <b>Goldman Sachs</b>&nbsp;analyst Chris Shibutani initiated coverage on Pfizer and Johnson &amp; Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.</p><p><blockquote><b>高盛</b>分析师Chris Shibutani周五开始对辉瑞和强生公司进行报道，对这两只备受瞩目的医疗保健行业股票给予中性推荐。</blockquote></p><p> Shibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech&nbsp;<b>BioNTech</b>.</p><p><blockquote>尽管辉瑞与德国生物技术公司开发的Comirnaty冠状病毒疫苗取得了巨大成功，但涩谷对他认为辉瑞的未来有些阴云密布感到担忧<b>BioNTech</b>.</blockquote></p><p> \"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.</p><p><blockquote>他写道：“我们对[辉瑞]的看法归结为，我们估计其当前估值的三分之一左右归因于COVID-19疫苗和治疗[产品]，我们认为两者的发展轨迹仍然高度不确定。”</blockquote></p><p> As for Johnson &amp; Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.</p><p><blockquote>至于强生公司，预言家认为该股的估值也相当合理。然而，他对公司的潜力持更为乐观的态度。</blockquote></p><p> \"With [Johnson &amp; Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson &amp; Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.</p><p><blockquote>“随着[强生]正处于组织多个领域的转型之中……我们看到了可能性——即使是在[强生]规模和范围的组织内——开发更多潜在的颠覆性机会在我们看来，这可能会重塑投资论点，”他写道。</blockquote></p><p> Last month, Johnson &amp; Johnson announced plans to spin off its sprawlingconsumer healthcare division.</p><p><blockquote>上个月，强生公司宣布计划剥离其庞大的消费者医疗保健部门。</blockquote></p><p> Shibutani's price target on Pfizer stock is $51 per share, and that for Johnson &amp; Johnson is $161.</p><p><blockquote>Shibutani对辉瑞股票的目标价为每股51美元，强生公司的目标价为每股161美元。</blockquote></p><p> Now what</p><p><blockquote>现在怎么办</blockquote></p><p> Pfizer and Johnson &amp; Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.</p><p><blockquote>辉瑞和强生公司无疑正在进入一些不确定的水域——无论是冠状病毒，还是后者公司显然迫在眉睫的分拆。不过，在我看来，这两家公司在各自疫苗之外的众多产品领域都拥有雄厚的实力，因此投资者不应因高盛的最新评估而过于气馁。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer and Johnson & Johnson Fell on Friday<blockquote>辉瑞和强生周五为何下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer and Johnson & Johnson Fell on Friday<blockquote>辉瑞和强生周五为何下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-12-18 13:14</span>\n</p>\n</h4>\n</header>\n<article>\n<p>What happened</p><p><blockquote>发生了什么</blockquote></p><p> Two prominent U.S. coronavirus stocks ended the week on a down note.&nbsp;<a href=\"https://laohu8.com/S/PFE\"><b>Pfizer</b></a>&nbsp;and&nbsp;<a href=\"https://laohu8.com/S/JNJ\"><b>Johnson &amp; Johnson</b></a>&nbsp;both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.</p><p><blockquote>两只著名的美国冠状病毒股票本周收盘下跌。<a href=\"https://laohu8.com/S/PFE\"><b>辉瑞</b></a>和<a href=\"https://laohu8.com/S/JNJ\"><b>强生公司</b></a>当日均跌近3%。此前，一家著名投资银行对其当前前景持相当冷淡的看法。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c6a2f152eebbe10f5ab65a99815f461c\" tg-width=\"975\" tg-height=\"637\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> So what</p><p><blockquote>那又怎样</blockquote></p><p> <b>Goldman Sachs</b>&nbsp;analyst Chris Shibutani initiated coverage on Pfizer and Johnson &amp; Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.</p><p><blockquote><b>高盛</b>分析师Chris Shibutani周五开始对辉瑞和强生公司进行报道，对这两只备受瞩目的医疗保健行业股票给予中性推荐。</blockquote></p><p> Shibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech&nbsp;<b>BioNTech</b>.</p><p><blockquote>尽管辉瑞与德国生物技术公司开发的Comirnaty冠状病毒疫苗取得了巨大成功，但涩谷对他认为辉瑞的未来有些阴云密布感到担忧<b>BioNTech</b>.</blockquote></p><p> \"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.</p><p><blockquote>他写道：“我们对[辉瑞]的看法归结为，我们估计其当前估值的三分之一左右归因于COVID-19疫苗和治疗[产品]，我们认为两者的发展轨迹仍然高度不确定。”</blockquote></p><p> As for Johnson &amp; Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.</p><p><blockquote>至于强生公司，预言家认为该股的估值也相当合理。然而，他对公司的潜力持更为乐观的态度。</blockquote></p><p> \"With [Johnson &amp; Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson &amp; Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.</p><p><blockquote>“随着[强生]正处于组织多个领域的转型之中……我们看到了可能性——即使是在[强生]规模和范围的组织内——开发更多潜在的颠覆性机会在我们看来，这可能会重塑投资论点，”他写道。</blockquote></p><p> Last month, Johnson &amp; Johnson announced plans to spin off its sprawlingconsumer healthcare division.</p><p><blockquote>上个月，强生公司宣布计划剥离其庞大的消费者医疗保健部门。</blockquote></p><p> Shibutani's price target on Pfizer stock is $51 per share, and that for Johnson &amp; Johnson is $161.</p><p><blockquote>Shibutani对辉瑞股票的目标价为每股51美元，强生公司的目标价为每股161美元。</blockquote></p><p> Now what</p><p><blockquote>现在怎么办</blockquote></p><p> Pfizer and Johnson &amp; Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.</p><p><blockquote>辉瑞和强生公司无疑正在进入一些不确定的水域——无论是冠状病毒，还是后者公司显然迫在眉睫的分拆。不过，在我看来，这两家公司在各自疫苗之外的众多产品领域都拥有雄厚的实力，因此投资者不应因高盛的最新评估而过于气馁。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/12/17/why-pfizer-and-johnson-johnson-fell-on-friday/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1109831591","content_text":"What happened\nTwo prominent U.S. coronavirus stocks ended the week on a down note. Pfizer and Johnson & Johnson both fell on the day by nearly 3%. This followed a prominent investment bank's rather lukewarm take on their current prospects.\n\nSo what\nGoldman Sachs analyst Chris Shibutani initiated coverage on Pfizer and Johnson & Johnson on Friday, tagging both high-profile healthcare industry stocks with neutral recommendations.\nShibutani is concerned with what he considers to be Pfizer's somewhat cloudy future, despite the great success of the Comirnaty coronavirus vaccine it developed with Germanbiotech BioNTech.\n\"Our views on [Pfizer] come down to that we estimate around one-third of its current valuation is attributed to the COVID-19 vaccine and therapeutic [products], and we feel the trajectory for both remains highly uncertain,\" he wrote.\nAs for Johnson & Johnson, the prognosticator feels the stock is also fairly valued. However, he sounded a more optimistic note about the company's potential.\n\"With [Johnson & Johnson] in the midst of transitions across several domains for the organization ... we see possibilities -- even within an organization of [Johnson & Johnson]'s scale and scope -- for additional potentially disruptive opportunities to develop that could reshape the investment thesis, in our view,\" he wrote.\nLast month, Johnson & Johnson announced plans to spin off its sprawlingconsumer healthcare division.\nShibutani's price target on Pfizer stock is $51 per share, and that for Johnson & Johnson is $161.\nNow what\nPfizer and Johnson & Johnson are certainly heading into some uncertain waters -- both with the coronavirus and, in the latter company's case, the apparently looming spinoff. To my mind, though, the two companies have plenty of strength in numerous product areas outside of their respective vaccines, so investors shouldn't be too discouraged by Goldman Sachs' latest evaluations.","news_type":1,"symbols_score_info":{"PFE":0.9,"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":2606,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600550505,"gmtCreate":1638177679665,"gmtModify":1638177748090,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"[财迷]&nbsp;","listText":"[财迷]&nbsp;","text":"[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600550505","repostId":"1106015985","repostType":2,"isVote":1,"tweetType":1,"viewCount":884,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699238053,"gmtCreate":1639805119710,"gmtModify":1639805119710,"author":{"id":"4089880892731870","authorId":"4089880892731870","name":"burstthepulp","avatar":"https://static.tigerbbs.com/061afaafc3ff1f0ee492256bbd9cdb31","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4089880892731870","authorIdStr":"4089880892731870"},"themes":[],"htmlText":"buy at dip?&nbsp;[Cool]&nbsp;","listText":"buy at dip?&nbsp;[Cool]&nbsp;","text":"buy at dip? [Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699238053","repostId":"1113352768","repostType":4,"repost":{"id":"1113352768","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639752492,"share":"https://www.laohu8.com/m/news/1113352768?lang=zh_CN&edition=full","pubTime":"2021-12-17 22:48","market":"us","language":"en","title":"Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group<blockquote>由于印度暂停2019年与Future Group的交易，亚马逊早盘下跌近2%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1113352768","media":"Tiger Newspress","summary":"Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group.India's ","content":"<p>Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group.<img src=\"https://static.tigerbbs.com/ecaa54686b8d8b0541b8769a2aa237a3\" tg-width=\"766\" tg-height=\"567\" width=\"100%\" height=\"auto\">India's antitrust body on Friday suspended Amazon.com's 2019 deal with Future Group following a review of allegations that the U.S. e-commerce giant had concealed information while seeking regulatory approval.</p><p><blockquote>由于印度暂停2019年与Future Group的交易，亚马逊早盘下跌近2%。印度反垄断机构周五暂停了亚马逊2019年与Future Group的交易，此前印度对这家美国电子商务巨头在寻求监管机构批准时隐瞒信息的指控进行了审查。</blockquote></p><p> The unprecedented step taken by the Competition Commission of India (CCI) could have far-reaching consequences on Amazon's legal battles with now estranged partner Future. The U.S. firm has for months successfully used the terms of its toehold $200 million investment in 2019 to block Future's attempt to sell retail assets to Reliance Industries for $3.4 billion.</p><p><blockquote>印度（CCI）竞争委员会采取的前所未有的举措可能会对亚马逊与现已疏远的合作伙伴Future的法律斗争产生深远的影响。几个月来，这家美国公司成功利用其2019年2亿美元投资的条款，阻止了Future以34亿美元的价格向Reliance Industries出售零售资产的企图。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group<blockquote>由于印度暂停2019年与Future Group的交易，亚马逊早盘下跌近2%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group<blockquote>由于印度暂停2019年与Future Group的交易，亚马逊早盘下跌近2%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-17 22:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group.<img src=\"https://static.tigerbbs.com/ecaa54686b8d8b0541b8769a2aa237a3\" tg-width=\"766\" tg-height=\"567\" width=\"100%\" height=\"auto\">India's antitrust body on Friday suspended Amazon.com's 2019 deal with Future Group following a review of allegations that the U.S. e-commerce giant had concealed information while seeking regulatory approval.</p><p><blockquote>由于印度暂停2019年与Future Group的交易，亚马逊早盘下跌近2%。印度反垄断机构周五暂停了亚马逊2019年与Future Group的交易，此前印度对这家美国电子商务巨头在寻求监管机构批准时隐瞒信息的指控进行了审查。</blockquote></p><p> The unprecedented step taken by the Competition Commission of India (CCI) could have far-reaching consequences on Amazon's legal battles with now estranged partner Future. The U.S. firm has for months successfully used the terms of its toehold $200 million investment in 2019 to block Future's attempt to sell retail assets to Reliance Industries for $3.4 billion.</p><p><blockquote>印度（CCI）竞争委员会采取的前所未有的举措可能会对亚马逊与现已疏远的合作伙伴Future的法律斗争产生深远的影响。几个月来，这家美国公司成功利用其2019年2亿美元投资的条款，阻止了Future以34亿美元的价格向Reliance Industries出售零售资产的企图。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1113352768","content_text":"Amazon slid nearly 2% in morning trading as India suspended its 2019 deal with Future Group.India's antitrust body on Friday suspended Amazon.com's 2019 deal with Future Group following a review of allegations that the U.S. e-commerce giant had concealed information while seeking regulatory approval.\nThe unprecedented step taken by the Competition Commission of India (CCI) could have far-reaching consequences on Amazon's legal battles with now estranged partner Future. The U.S. firm has for months successfully used the terms of its toehold $200 million investment in 2019 to block Future's attempt to sell retail assets to Reliance Industries for $3.4 billion.","news_type":1,"symbols_score_info":{"AMZN":0.9}},"isVote":1,"tweetType":1,"viewCount":2284,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}